[Congressional Record (Bound Edition), Volume 152 (2006), Part 18]
[House]
[Pages 22877-22894]
[From the U.S. Government Publishing Office, www.gpo.gov]




   OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION ACT OF 2006

  Mr. SOUDER. Madam Speaker, I move to suspend the rules and pass the 
bill (H.R. 6344) to reauthorize the Office of National Drug Control 
Policy Act, as amended.
  The Clerk read as follows:

                               H.R. 6344

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. SHORT TITLE, REFERENCE, AND TABLE OF CONTENTS.

       (a) Short Title.--This Act may be cited as the ``Office of 
     National Drug Control Policy Reauthorization Act of 2006''.
       (b) Amendment of Office of National Drug Control Policy 
     Reauthorization Act of 1998.--Except as otherwise expressly 
     provided, whenever in this Act an amendment or repeal is 
     expressed in terms of an amendment to, or repeal of, a 
     section or other provision, the reference shall be considered 
     to be made to a section or other provision of the Office of 
     National Drug Control Policy Reauthorization Act of 1998 
     (Public Law 105-277; 21 U.S.C. 1701 et seq.).
       (c) Table of Contents.--The table of contents for this Act 
     is as follows:

Sec. 1. Short title, reference, and table of contents.

  TITLE I--ORGANIZATION OF OFFICE OF NATIONAL DRUG CONTROL POLICY AND 
                       ROLES AND RESPONSIBILITIES

Sec. 101. Amendments to definitions.
Sec. 102. Establishment of the Office of National Drug Control Policy.
Sec. 103. Appointment and responsibilities of the Director.
Sec. 104. Amendments to ensure coordination with other agencies.
Sec. 105. Budgetary matters.

              TITLE II--THE NATIONAL DRUG CONTROL STRATEGY

Sec. 201. Annual preparation and submission of National Drug Control 
              Strategy.
Sec. 202. Performance measurements.
Sec. 203. Annual report requirement.

            TITLE III--HIGH INTENSITY DRUG TRAFFICKING AREAS

Sec. 301. High Intensity Drug Trafficking Areas Program.
Sec. 302. Funding for certain high intensity drug trafficking areas.
Sec. 303. Assessment.

                          TITLE IV--TECHNOLOGY

Sec. 401. Counterdrug Technology Assessment Center.

                 TITLE V--NATIONAL YOUTH MEDIA CAMPAIGN

Sec. 501. National Youth Anti-Drug Media Campaign.

       TITLE VI--AUTHORIZATIONS AND EXTENSION OF TERMINATION DATE

Sec. 601. Authorization of appropriations.
Sec. 602. Extension of termination date.

                     TITLE VII--ANTI-DOPING AGENCY

Sec. 701. Designation of United States Anti-Doping Agency.
Sec. 702. Records, audit, and report.
Sec. 703. Authorization of appropriations.

                   TITLE VIII--DRUG-FREE COMMUNITIES

Sec. 801. Reauthorization.
Sec. 802. Suspension of grants.
Sec. 803. Grant award increase.
Sec. 804. Prohibition on additional eligibility criteria.
Sec. 805. National Community Anti-Drug Coalition Institute.

              TITLE IX--NATIONAL GUARD COUNTERDRUG SCHOOLS

Sec. 901. National Guard counterdrug schools.

TITLE X--NATIONAL METHAMPHETAMINE INFORMATION CLEARINGHOUSE ACT OF 2006

Sec. 1001. Short title.
Sec. 1002. Definitions.
Sec. 1003. Establishment of clearinghouse and advisory council.
Sec. 1004. NMIC requirements and review.
Sec. 1005. Authorization of appropriations.

                   TITLE XI--MISCELLANEOUS PROVISIONS

Sec. 1101. Repeals.
Sec. 1102. Controlled Substances Act amendments.
Sec. 1103. Report on law enforcement intelligence sharing.
Sec. 1104. Requirement for South American heroin strategy.

[[Page 22878]]

Sec. 1105. Model acts.
Sec. 1106. Study on iatrogenic addiction associated with prescription 
              opioid analgesic drugs.
Sec. 1107. Requirement for strategy to stop Internet advertising of 
              prescription medicines without a prescription.
Sec. 1108. Requirement for study on diversion and inappropriate uses of 
              prescription drugs.
Sec. 1109. Requirement for Afghan Heroin Strategy.
Sec. 1110. Requirement for Southwest Border Counternarcotics Strategy.
Sec. 1111. Requirement for Scientific Study of Mycoherbicide in Illicit 
              Drug Crop Eradication.
Sec. 1112. Requirement for Study of State Precursor Chemical Control 
              Laws.
Sec. 1113. Requirement for Study of Drug Endangered Children Programs.
Sec. 1114. Study on drug court hearings in nontraditional places.
Sec. 1115. Report on tribal Government participation in HIDTA process.
Sec. 1116. Report on school drug testing.
Sec. 1117. Report on ONDCP performance bonuses.
Sec. 1118. Requirement for disclosure of Federal sponsorship of all 
              Federal advertising or other communication materials.
Sec. 1119. Awards for demonstration programs by local partnerships to 
              coerce abstinence in chronic hard-drug users under 
              community supervision through the use of drug testing and 
              sanctions.
Sec. 1120. Policy relating to syringe exchange programs.

  TITLE I--ORGANIZATION OF OFFICE OF NATIONAL DRUG CONTROL POLICY AND 
                       ROLES AND RESPONSIBILITIES

     SEC. 101. AMENDMENTS TO DEFINITIONS.

       (a) Demand Reduction.--Section 702(1) is amended--
       (1) in subparagraph (F), by striking ``and'' after the 
     semicolon;
       (2) in paragraph (G), by striking the period at the end and 
     inserting ``, including the testing of employees;''; and
       (3) by adding at the end the following:
       ``(H) interventions for drug abuse and dependence;
       ``(I) international drug control coordination and 
     cooperation with respect to activities described in this 
     paragraph; and
       ``(J) international drug abuse education, prevention, 
     treatment, research, rehabilitation activities, and 
     interventions for drug abuse and dependence.''.
       (b) National Drug Control Program.--Section 702(6) is 
     amended by adding before the period the following: ``, 
     including any activities involving supply reduction, demand 
     reduction, or State, local, and tribal affairs''.
       (c) Program Change.--Section 702(7) is amended by--
       (1) striking ``National Foreign Intelligence Program,'' and 
     inserting ``National Intelligence Program,''; and
       (2) inserting after ``Related Activities,'' the following: 
     ``or (for purposes of section 704(d)) an agency that is 
     described in section 530C(a) of title 28, United States 
     Code,''.
       (d) Office.--Section 702(9) is amended by striking 
     ``implicates'' and inserting ``indicates''.
       (e) State, Local, and Tribal Affairs.--Paragraph (10) of 
     section 702 is amended to read as follows:
       ``(10) State, local, and tribal affairs.--The term `State, 
     local, and tribal affairs' means domestic activities 
     conducted by a National Drug Control Program agency that are 
     intended to reduce the availability and use of illegal drugs, 
     including--
       ``(A) coordination and enhancement of Federal, State, 
     local, and tribal law enforcement drug control efforts;
       ``(B) coordination and enhancement of efforts among 
     National Drug Control Program agencies and State, local, and 
     tribal demand reduction and supply reduction agencies;
       ``(C) coordination and enhancement of Federal, State, 
     local, and tribal law enforcement initiatives to gather, 
     analyze, and disseminate information and law enforcement 
     intelligence relating to drug control among domestic law 
     enforcement agencies; and
       ``(D) other coordinated and joint initiatives among 
     Federal, State, local, and tribal agencies to promote 
     comprehensive drug control strategies designed to reduce the 
     demand for, and the availability of, illegal drugs.''.
       (f) Supply Reduction.--Section 702(11) is amended to read 
     as follows:
       ``(11) Supply reduction.--The term `supply reduction' means 
     any activity or program conducted by a National Drug Control 
     Program agency that is intended to reduce the availability or 
     use of illegal drugs in the United States or abroad, 
     including--
       ``(A) law enforcement outside the United States;
       ``(B) source country programs, including economic 
     development programs primarily intended to reduce the 
     production or trafficking of illicit drugs;
       ``(C) activities to control international trafficking in, 
     and availability of, illegal drugs, including--
       ``(i) accurate assessment and monitoring of international 
     drug production and interdiction programs and policies; and
       ``(ii) coordination and promotion of compliance with 
     international treaties relating to the production, 
     transportation, or interdiction of illegal drugs;
       ``(D) activities to conduct and promote international law 
     enforcement programs and policies to reduce the supply of 
     drugs; and
       ``(E) activities to facilitate and enhance the sharing of 
     domestic and foreign intelligence information among National 
     Drug Control Program agencies, relating to the production and 
     trafficking of drugs in the United States and in foreign 
     countries.''.
       (g) Definitions of Appropriate Congressional Committees and 
     Law Enforcement.--Section 702 is amended by adding at the end 
     the following:
       ``(12) Appropriate congressional committees.--Except where 
     otherwise provided, the term `appropriate congressional 
     committees' means the Committee on the Judiciary, the 
     Committee on Appropriations, and the Caucus on International 
     Narcotics Control of the Senate and the Committee on 
     Government Reform, the Committee on the Judiciary, and the 
     Committee on Appropriations of the House of Representatives.
       ``(13) Law enforcement.--The term `law enforcement' or 
     `drug law enforcement' means all efforts by a Federal, State, 
     local, or tribal government agency to enforce the drug laws 
     of the United States or any State, including investigation, 
     arrest, prosecution, and incarceration or other punishments 
     or penalties.''.

     SEC. 102. ESTABLISHMENT OF THE OFFICE OF NATIONAL DRUG 
                   CONTROL POLICY.

       (a) Responsibilities.--Section 703(a) is amended to read as 
     follows:
       ``(a) Establishment of Office.--There is established in the 
     Executive Office of the President an Office of National Drug 
     Control Policy, which shall--
       ``(1) develop national drug control policy;
       ``(2) coordinate and oversee the implementation of the 
     national drug control policy;
       ``(3) assess and certify the adequacy of National Drug 
     Control Programs and the budget for those programs; and
       ``(4) evaluate the effectiveness of the national drug 
     control policy and the National Drug Control Program 
     agencies' programs, by developing and applying specific goals 
     and performance measurements.''.
       (b) Positions.--Section 703(b) is amended to read as 
     follows:
       ``(b) Director of National Drug Control Policy and Deputy 
     Directors.--
       ``(1) Director.--There shall be a Director of National Drug 
     Control Policy who shall head the Office (referred to in this 
     Act as the `Director') and shall hold the same rank and 
     status as the head of an executive department listed in 
     section 101 of title 5, United States Code.
       ``(2) Deputy director.--There shall be a Deputy Director of 
     National Drug Control Policy who shall report directly to the 
     Director (referred to in this Act as the `Deputy Director').
       ``(3) Other deputy directors.--
       ``(A) In general.--There shall be a Deputy Director for 
     Demand Reduction, a Deputy Director for Supply Reduction, and 
     a Deputy Director for State, Local, and Tribal Affairs.
       ``(B) Reporting.--The Deputy Director for Demand Reduction, 
     the Deputy Director for Supply Reduction, and the Deputy 
     Director for State, Local, and Tribal Affairs shall report 
     directly to the Deputy Director of the Office of National 
     Drug Control Policy.
       ``(C) Deputy director for demand reduction.--The Deputy 
     Director for Demand Reduction shall be responsible for the 
     activities in subparagraphs (A) through (H) of section 
     702(l).
       ``(D) Deputy director for supply reduction.--The Deputy 
     Director for Supply Reduction shall--
       ``(i) have substantial experience and expertise in drug 
     interdiction and other supply reduction activities; and
       ``(ii) be responsible for the activities in subparagraphs 
     (A) through (C) in section 702(11).
       ``(E) Deputy director for state, local, and tribal 
     affairs.--The Deputy Director for State, Local, and Tribal 
     Affairs shall be responsible for the activities--
       ``(i) in subparagraphs (A) through (D) of section 702(10);
       ``(ii) in section 707, the High Intensity Drug Trafficking 
     Areas Program; and
       ``(iii) in section 708, the Counterdrug Technology 
     Assessment Center.''.

     SEC. 103. APPOINTMENT AND RESPONSIBILITIES OF THE DIRECTOR.

       (a) Succession.--Section 704(a) is amended by amending 
     paragraph (3) to read as follows:
       ``(3) Acting director.--If the Director dies, resigns, or 
     is otherwise unable to perform the functions and duties of 
     the office, the Deputy Director shall perform the functions 
     and duties of the Director temporarily in an acting capacity 
     pursuant to subchapter III of chapter 33 of title 5, United 
     States Code.''.
       (b) Responsibilities.--Section 704(b) is amended--
       (1) in paragraph (4), by striking ``Federal departments and 
     agencies engaged in drug enforcement'' and inserting 
     ``National Drug Control Program agencies'';

[[Page 22879]]

       (2) in paragraph (7), by inserting after ``President'' the 
     following: ``and the appropriate congressional committees'';
       (3) in paragraph (13), by striking ``(beginning in 1999)'';
       (4) by striking paragraph (14) and inserting the following:
       ``(14) shall submit to the appropriate congressional 
     committees on an annual basis, not later than 60 days after 
     the date of the last day of the applicable period, a summary 
     of--
       ``(A) each of the evaluations received by the Director 
     under paragraph (13); and
       ``(B) the progress of each National Drug Control Program 
     agency toward the drug control program goals of the agency 
     using the performance measures for the agency developed under 
     section 706(c);'';
       (5) in paragraph (15), by striking subparagraph (C) and 
     inserting the following:
       ``(C) supporting the substance abuse information 
     clearinghouse administered by the Administrator of the 
     Substance Abuse and Mental Health Services Administration and 
     established in section 501(d)(16) of the Public Health 
     Service Act by--
       ``(i) encouraging all National Drug Control Program 
     agencies to provide all appropriate and relevant information; 
     and
       ``(ii) supporting the dissemination of information to all 
     interested entities;''; and
       (6) by inserting at the end the following:
       ``(16) shall coordinate with the private sector to promote 
     private research and development of medications to treat 
     addiction;
       ``(17) shall seek the support and commitment of State, 
     local, and tribal officials in the formulation and 
     implementation of the National Drug Control Strategy;
       ``(18) shall monitor and evaluate the allocation of 
     resources among Federal law enforcement agencies in response 
     to significant local and regional drug trafficking and 
     production threats;
       ``(19) shall submit an annual report to Congress detailing 
     how the Office of National Drug Control Policy has consulted 
     with and assisted State, local, and tribal governments with 
     respect to the formulation and implementation of the National 
     Drug Control Strategy and other relevant issues; and
       ``(20) shall, within 1 year after the date of the enactment 
     of the Office of National Drug Control Policy Reauthorization 
     Act of 2006, report to Congress on the impact of each Federal 
     drug reduction strategy upon the availability, addiction 
     rate, use rate, and other harms of illegal drugs.''.
       (c) Review and Certification of National Drug Control 
     Program Budget.--Section 704(c)(3) is amended--
       (1) in subparagraph (C)(iii), by inserting ``and the 
     appropriate congressional committees,'' after ``House of 
     Representatives''; and
       (2) in subparagraph (D)(ii)(II)(bb), by inserting ``and the 
     appropriate congressional committees,'' after ``House of 
     Representatives''.
       (d) Powers of Director.--Section 704(d) is amended--
       (1) in paragraph (9), by striking ``Strategy; and'' and 
     inserting ``Strategy and notify the appropriate congressional 
     committees of any fund control notice issued in accordance 
     with section 704(f)(5);''; and
       (2) in paragraph (10), by inserting before the period the 
     following: ``and section 706 of the Department of State 
     Authorization Act for Fiscal Year 2003 (22 U.S.C. 229j-1)''.
       (e) Fund Control Notices.--Section 704(f) is amended by 
     adding at the end the following:
       ``(4) Congressional notice.--A copy of each fund control 
     notice shall be transmitted to the appropriate congressional 
     committees.
       ``(5) Restrictions.--The Director shall not issue a fund 
     control notice to direct that all or part of an amount 
     appropriated to the National Drug Control Program agency 
     account be obligated, modified, or altered in any manner--
       ``(A) contrary, in whole or in part, to a specific 
     appropriation; or
       ``(B) contrary, in whole or in part, to the expressed 
     intent of Congress.''.
       (f) Drug Interdiction.--
       (1) In general.--Section 711 is amended by adding at the 
     end the following:

     ``SEC. 711. DRUG INTERDICTION COORDINATOR AND COMMITTEE.

       ``(a) United States Interdiction Coordinator.--
       ``(1) In general.--The United States Interdiction 
     Coordinator shall perform the duties of that position 
     described in paragraph (2) and such other duties as may be 
     determined by the Director with respect to coordination of 
     efforts to interdict illicit drugs from entering the United 
     States.
       ``(2) Responsibilities.--The United States Interdiction 
     Coordinator shall be responsible to the Director for--
       ``(A) coordinating the interdiction activities of the 
     National Drug Control Program agencies to ensure consistency 
     with the National Drug Control Strategy;
       ``(B) on behalf of the Director, developing and issuing, on 
     or before March 1 of each year and in accordance with 
     paragraph (3), a National Interdiction Command and Control 
     Plan to ensure the coordination and consistency described in 
     subparagraph (A);
       ``(C) assessing the sufficiency of assets committed to 
     illicit drug interdiction by the relevant National Drug 
     Control Program agencies; and
       ``(D) advising the Director on the efforts of each National 
     Drug Control Program agency to implement the National 
     Interdiction Command and Control Plan.
       ``(3) Staff.--The Director shall assign such permanent 
     staff of the Office as he considers appropriate to assist the 
     United States Interdiction Coordinator to carry out the 
     responsibilities described in paragraph (2), and may also, at 
     his discretion, request that appropriate National Drug 
     Control Program agencies detail or assign staff to the Office 
     of Supply Reduction for that purpose.
       ``(4) National interdiction command and control plan.--
       ``(A) Purposes.--The National Interdiction Command and 
     Control Plan shall--
       ``(i) set forth the Government's strategy for drug 
     interdiction;
       ``(ii) state the specific roles and responsibilities of the 
     relevant National Drug Control Program agencies for 
     implementing that strategy; and
       ``(iii) identify the specific resources required to enable 
     the relevant National Drug Control Program agencies to 
     implement that strategy.
       ``(B) Consultation with other agencies.--The United States 
     Interdiction Coordinator shall issue the National 
     Interdiction Command and Control Plan in consultation with 
     the other members of the Interdiction Committee described in 
     subsection (b).
       ``(C) Limitation.--The National Interdiction Command and 
     Control Plan shall not change existing agency authorities or 
     the laws governing interagency relationships, but may include 
     recommendations about changes to such authorities or laws.
       ``(D) Report to congress.--On or before March 1 of each 
     year, the United States Interdiction Coordinator shall 
     provide a report on behalf of the Director to the appropriate 
     congressional committees, to the Committee on Armed Services 
     and the Committee on Homeland Security of the House of 
     Representatives, and to the Committee on Homeland Security 
     and Governmental Affairs and the Committee on Armed Services 
     of the Senate, which shall include--
       ``(i) a copy of that year's National Interdiction Command 
     and Control Plan;
       ``(ii) information for the previous 10 years regarding the 
     number and type of seizures of drugs by each National Drug 
     Control Program agency conducting drug interdiction 
     activities, as well as statistical information on the 
     geographic areas of such seizures; and
       ``(iii) information for the previous 10 years regarding the 
     number of air and maritime patrol hours undertaken by each 
     National Drug Control Program agency conducting drug 
     interdiction activities, as well as statistical information 
     on the geographic areas in which such patrol hours took 
     place.
       ``(E) Treatment of classified or law enforcement sensitive 
     information.--Any content of the report described in 
     subparagraph (D) that involves information classified under 
     criteria established by an Executive order, or the public 
     disclosure of which, as determined by the Director, the 
     Director of National Intelligence, or the head of any Federal 
     Government agency the activities of which are described in 
     the plan, would be detrimental to the law enforcement or 
     national security activities of any Federal, State, or local 
     agency, shall be presented to Congress separately from the 
     rest of the report.
       ``(b) Interdiction Committee.--
       ``(1) In general.--The Interdiction Committee shall meet 
     to--
       ``(A) discuss and resolve issues related to the 
     coordination, oversight and integration of international, 
     border, and domestic drug interdiction efforts in support of 
     the National Drug Control Strategy;
       ``(B) review the annual National Interdiction Command and 
     Control Plan, and provide advice to the Director and the 
     United States Interdiction Coordinator concerning that plan; 
     and
       ``(C) provide such other advice to the Director concerning 
     drug interdiction strategy and policies as the committee 
     determines is appropriate.
       ``(2) Chairman.--The Director shall designate one of the 
     members of the Interdiction Committee to serve as chairman.
       ``(3) Meetings.--The members of the Interdiction Committee 
     shall meet, in person and not through any delegate or 
     representative, at least once per calendar year, prior to 
     March 1. At the call of either the Director or the current 
     chairman, the Interdiction Committee may hold additional 
     meetings, which shall be attended by the members either in 
     person, or through such delegates or representatives as they 
     may choose.
       ``(4) Report.--Not later than September 30 of each year, 
     the chairman of the Interdiction Committee shall submit a 
     report to the Director and to the appropriate congressional 
     committees describing the results of the meetings and any 
     significant findings of the Committee during the previous 12 
     months. Any content of such a report that involves 
     information classified under criteria established by an 
     Executive order, or whose public disclosure, as determined by 
     the Director, the chairman, or any member, would be 
     detrimental to the law enforcement or national security 
     activities of any Federal, State, local, or tribal agency, 
     shall be

[[Page 22880]]

     presented to Congress separately from the rest of the report. 
     by striking subsection (d) and redesignating subsections (e), 
     (f), and (g) as subsections (d), (e), and (f), 
     respectively.''.
       (2) Conforming amendment to homeland security act of 
     2002.--Section 878 of the Homeland Security Act of 2002 (6 
     U.S.C. 458) is amended--
       (A) in subsection (c), by striking ``Except as provided in 
     subsection (d), the'' and inserting ``The''; and
       (B) by striking subsection (d) and redesignating 
     subsections (e), (f), and (g) as subsections (d), (e), and 
     (f), respectively.
       (3) Technical amendments.--Section 704 (21 U.S.C. 1703) is 
     amended--
       (A) by amending subsection (g) to read as follows:
       ``(g) Inapplicability to Certain Programs.--The provisions 
     of this section shall not apply to the National Intelligence 
     Program, the Joint Military Intelligence Program, and 
     Tactical and Related Activities, unless such program or an 
     element of such program is designated as a National Drug 
     Control Program--
       ``(1) by the President; or
       ``(2) jointly by--
       ``(A) in the case of the National Intelligence Program, the 
     Director and the Director of National Intelligence; or
       ``(B) in the case of the Joint Military Intelligence 
     Program and Tactical and Related Activities, the Director, 
     the Director of National Intelligence, and the Secretary of 
     Defense.''; and
       (B) by amending subsection (h) to read as follows:
       ``(h) Construction.--Nothing in this Act shall be construed 
     as derogating the authorities and responsibilities of the 
     Director of National Intelligence or the Director of the 
     Central Intelligence Agency contained in the National 
     Security Act of 1947 (50 U.S.C. 401 et seq.), the Central 
     Intelligence Agency Act of 1949 (50 U.S.C. 403a et seq.), or 
     any other law.''.

     SEC. 104. AMENDMENTS TO ENSURE COORDINATION WITH OTHER 
                   AGENCIES.

       Section 705 is amended--
       (1) in subsection (a)(1)(A), by striking ``abuse'';
       (2) in subsection (a)(2)(A), by striking ``Director of 
     Central Intelligence'' and inserting ``Director of National 
     Intelligence'';
       (3) in subsection (a)(2)(B), by striking ``Director of 
     Central Intelligence'' and inserting ``Director of National 
     Intelligence and the Director of the Central Intelligence 
     Agency'';
       (4) by amending subsection (a)(3) to read as follows:
       ``(3) Required reports.--
       ``(A) Secretaries of the interior and agriculture.--Not 
     later than July 1 of each year, the Secretaries of 
     Agriculture and the Interior shall jointly submit to the 
     Director and the appropriate congressional committees an 
     assessment of the quantity of illegal drug cultivation and 
     manufacturing in the United States on lands owned or under 
     the jurisdiction of the Federal Government for the preceding 
     year.
       ``(B) Secretary of homeland security.--Not later than July 
     1 of each year, the Secretary of Homeland Security shall 
     submit to the Director and the appropriate congressional 
     committees information for the preceding year regarding--
       ``(i) the number and type of seizures of drugs by each 
     component of the Department of Homeland Security seizing 
     drugs, as well as statistical information on the geographic 
     areas of such seizures; and
       ``(ii) the number of air and maritime patrol hours 
     primarily dedicated to drug supply reduction missions 
     undertaken by each component of the Department of Homeland 
     Security.
       ``(C) Secretary of defense.--The Secretary of Defense 
     shall, by July 1 of each year, submit to the Director and the 
     appropriate congressional committees information for the 
     preceding year regarding the number of air and maritime 
     patrol hours primarily dedicated to drug supply reduction 
     missions undertaken by each component of the Department of 
     Defense.
       ``(D) Attorney general.--The Attorney General shall, by 
     July 1 of each year, submit to the Director and the 
     appropriate congressional committees information for the 
     preceding year regarding the number and type of--
       ``(i) arrests for drug violations;
       ``(ii) prosecutions for drug violations by United States 
     Attorneys; and
       ``(iii) seizures of drugs by each component of the 
     Department of Justice seizing drugs, as well as statistical 
     information on the geographic areas of such seizures.'';
       (5) in subsection (b)(2)(B), by striking ``Program'' and 
     inserting ``Strategy''; and
       (6) in subsection (c), by striking ``in'' and inserting 
     ``on''.

     SEC. 105. BUDGETARY MATTERS.

       (a) Submission of Drug Control Budget Requests.--Section 
     704(c)(1) is amended by adding at the end the following:
       ``(C) Content of drug control budget requests.--A drug 
     control budget request submitted by a department, agency, or 
     program under this paragraph shall include all requests for 
     funds for any drug control activity undertaken by that 
     department, agency, or program, including demand reduction, 
     supply reduction, and State, local, and tribal affairs, 
     including any drug law enforcement activities. If an activity 
     has both drug control and nondrug control purposes or 
     applications, the department, agency, or program shall 
     estimate by a documented calculation the total funds 
     requested for that activity that would be used for drug 
     control, and shall set forth in its request the basis and 
     method for making the estimate.''.
       (b) National Drug Control Budget Proposal.--
       (1) National organizations.--Section 704(c)(2) is amended 
     by inserting ``and the head of each major national 
     organization that represents law enforcement officers, 
     agencies, or associations'' after ``agency''.
       (2) Total budget.--Section 704(c)(2)(A) is amended by 
     inserting before the semicolon: ``and to inform Congress and 
     the public about the total amount proposed to be spent on all 
     supply reduction, demand reduction, State, local, and tribal 
     affairs, including any drug law enforcement, and other drug 
     control activities by the Federal Government, which shall 
     conform to the content requirements set forth in paragraph 
     (1)(C)''.
       (c) Review and Certification of National Drug Control 
     Program Budget.--Section 704(c)(3) is amended--
       (1) by redesignating subparagraphs (C) and (D) as 
     subparagraphs (D) and (E), respectively;
       (2) by inserting after subparagraph (B) the following new 
     subparagraph:
       ``(C) Specific requests.--The Director shall not confirm 
     the adequacy of any budget request that--
       ``(i) requests funding for Federal law enforcement 
     activities that do not adequately compensate for transfers of 
     drug enforcement resources and personnel to law enforcement 
     and investigation activities;
       ``(ii) requests funding for law enforcement activities on 
     the borders of the United States that do not adequately 
     direct resources to drug interdiction and enforcement;
       ``(iii) requests funding for drug treatment activities that 
     do not provide adequate results and accountability measures;
       ``(iv) requests funding for any activities of the Safe and 
     Drug-Free Schools Program that do not include a clear anti-
     drug message or purpose intended to reduce drug use;
       ``(v) requests funding for drug treatment activities that 
     do not adequately support and enhance Federal drug treatment 
     programs and capacity;
       ``(vi) requests funding for fiscal year 2007 for activities 
     of the Department of Education, unless it is accompanied by a 
     report setting forth a plan for providing expedited 
     consideration of student loan applications for all 
     individuals who submitted an application for any Federal 
     grant, loan, or work assistance that was rejected or denied 
     pursuant to 484(r)(1) of the Higher Education Act of 1965 (20 
     U.S.C. 1091(r)(1)) by reason of a conviction for a drug-
     related offense not occurring during a period of enrollment 
     for which the individual was receiving any Federal grant, 
     loan, or work assistance; and
       ``(vii) requests funding for the operations and management 
     of the Department of Homeland Security that does not include 
     a specific request for funds for the Office of 
     Counternarcotics Enforcement to carry out its 
     responsibilities under section 878 of the Homeland Security 
     Act of 2002 (6 U.S.C. 458).'';
       (3) in subparagraph (D)(iii), as so redesignated, by 
     inserting ``and the appropriate congressional committees'' 
     after ``House of Representatives''; and
       (4) in subparagraph (E)(ii)(II)(bb), as so redesignated, by 
     inserting ``and the appropriate congressional committees'' 
     after ``House of Representatives''.
       (d) Reprogramming and Transfer Requests.--Section 
     704(c)(4)(A) (21 U.S.C. 1703(c)(4)(A)) is amended--
       (1) by striking ``$5,000,000'' and inserting 
     ``$1,000,000''; and
       (2) adding at the end the following: ``If the Director has 
     not responded to a request for reprogramming subject to this 
     subparagraph within 30 days after receiving notice of the 
     request having been made, the request shall be deemed 
     approved by the Director under this subparagraph and 
     forwarded to Congress.''.
       (e) Powers of Director.--Section 704(d) is amended--
       (1) in paragraph (8)(D), by striking ``have been authorized 
     by Congress;'' and inserting ``authorized by law;'';
       (2) in paragraph (9), by striking ``Strategy; and'' and 
     inserting ``Strategy and notify the appropriate congressional 
     committees of any fund control notice issued; and''; and
       (3) in paragraph (10), by striking ``(22 U.S.C. 2291j).'' 
     and inserting ``(22 U.S.C. 2291j) and section 706 of the 
     Foreign Relations Authorization Act, Fiscal Year 2003 (22 
     U.S.C. 2291j-1).''.
       (f) Fund Control Notices.--Section 704(f) (21 U.S.C. 
     1703(f)) is amended by adding at the end the following:
       ``(4) Congressional notice.--A copy of each fund control 
     notice shall be transmitted to the appropriate congressional 
     committees.
       ``(5) Restrictions.--The Director shall not issue a fund 
     control notice to direct that all or part of an amount 
     appropriated to the National Drug Control Program agency 
     account be obligated, modified, or altered in any

[[Page 22881]]

     manner contrary, in whole or in part, to a specific 
     appropriation or statute.''.

              TITLE II--THE NATIONAL DRUG CONTROL STRATEGY

     SEC. 201. ANNUAL PREPARATION AND SUBMISSION OF NATIONAL DRUG 
                   CONTROL STRATEGY.

       Section 706 is amended to read as follows:

     ``SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND 
                   ASSESSMENT OF NATIONAL DRUG CONTROL STRATEGY.

       ``(a) Timing, Contents, and Process for Development and 
     Submission of National Drug Control Strategy.--
       ``(1) Timing.--Not later than February 1 of each year, the 
     President shall submit to Congress a National Drug Control 
     Strategy, which shall set forth a comprehensive plan for the 
     year to reduce illicit drug use and the consequences of such 
     illicit drug use in the United States by limiting the 
     availability of, and reducing the demand for, illegal drugs.
       ``(2) Contents.--
       ``(A) In general.--The National Drug Control Strategy 
     submitted under paragraph (1) shall include the following:
       ``(i) Comprehensive, research-based, long-range, 
     quantifiable goals for reducing illicit drug use and the 
     consequences of illicit drug use in the United States.
       ``(ii) Annual quantifiable and measurable objectives and 
     specific targets to accomplish long-term quantifiable goals 
     that the Director determines may be achieved during each year 
     beginning on the date on which the National Drug Control 
     Strategy is submitted.
       ``(iii) A 5-year projection for program and budget 
     priorities.
       ``(iv) A review of international, State, local, and private 
     sector drug control activities to ensure that the United 
     States pursues coordinated and effective drug control at all 
     levels of government.
       ``(v) An assessment of current illicit drug use (including 
     inhalants and steroids) and availability, impact of illicit 
     drug use, and treatment availability, which assessment shall 
     include--

       ``(I) estimates of drug prevalence and frequency of use as 
     measured by national, State, and local surveys of illicit 
     drug use and by other special studies of nondependent and 
     dependent illicit drug use;
       ``(II) illicit drug use in the workplace and the 
     productivity lost by such use; and
       ``(III) illicit drug use by arrestees, probationers, and 
     parolees.

       ``(vi) An assessment of the reduction of illicit drug 
     availability, as measured by--

       ``(I) the quantities of cocaine, heroin, marijuana, 
     methamphetamine, ecstasy, and other drugs available for 
     consumption in the United States;
       ``(II) the amount of marijuana, cocaine, heroin, 
     methamphetamine, ecstasy, and precursor chemicals and other 
     drugs entering the United States;
       ``(III) the number of illicit drug manufacturing 
     laboratories seized and destroyed and the number of hectares 
     of marijuana, poppy, and coca cultivated and destroyed 
     domestically and in other countries;
       ``(IV) the number of metric tons of marijuana, heroin, 
     cocaine, and methamphetamine seized and other drugs; and
       ``(V) changes in the price and purity of heroin, 
     methamphetamine, and cocaine, changes in the price of 
     ecstasy, and changes in tetrahydrocannabinol level of 
     marijuana and other drugs.

       ``(vii) An assessment of the reduction of the consequences 
     of illicit drug use and availability, which shall include--

       ``(I) the burden illicit drug users placed on hospital 
     emergency departments in the United States, such as the 
     quantity of illicit drug-related services provided;
       ``(II) the annual national health care cost of illicit drug 
     use; and
       ``(III) the extent of illicit drug-related crime and 
     criminal activity.

       ``(viii) A determination of the status of drug treatment in 
     the United States, by assessing--

       ``(I) public and private treatment utilization; and
       ``(II) the number of illicit drug users the Director 
     estimates meet diagnostic criteria for treatment.

       ``(ix) A review of the research agenda of the Counterdrug 
     Technology Assessment Center to reduce the availability and 
     abuse of drugs.
       ``(x) A summary of the efforts made to coordinate with 
     private sector entities to conduct private research and 
     development of medications to treat addiction by--

       ``(I) screening chemicals for potential therapeutic value;
       ``(II) developing promising compounds;
       ``(III) conducting clinical trials;
       ``(IV) seeking Food and Drug Administration approval for 
     drugs to treat addiction;
       ``(V) marketing the drug for the treatment of addiction;
       ``(VI) urging physicians to use the drug in the treatment 
     of addiction; and
       ``(VII) encouraging insurance companies to reimburse the 
     cost of the drug for the treatment of addiction.

       ``(xi) An assessment of Federal effectiveness in achieving 
     the National Drug Control Strategy for the previous year, 
     including a specific evaluation of whether the objectives and 
     targets for reducing illicit drug use for the previous year 
     were met and reasons for the success or failure of the 
     previous year's Strategy.
       ``(xii) A general review of the status of, and trends in, 
     demand reduction activities by private sector entities and 
     community-based organizations, including faith-based 
     organizations, to determine their effectiveness and the 
     extent of cooperation, coordination, and mutual support 
     between such entities and organizations and Federal, State, 
     local, and tribal government agencies.
       ``(xiii) Such additional statistical data and information 
     as the Director considers appropriate to demonstrate and 
     assess trends relating to illicit drug use, the effects and 
     consequences of illicit drug use (including the effects on 
     children of substance abusers), supply reduction, demand 
     reduction, drug-related law enforcement, and the 
     implementation of the National Drug Control Strategy.
       ``(xiv) A supplement reviewing the activities of each 
     individual National Drug Control Program agency during the 
     previous year with respect to the National Drug Control 
     Strategy and the Director's assessment of the progress of 
     each National Drug Control Program agency in meeting its 
     responsibilities under the National Drug Control Strategy.
       ``(B) Classified information.--Any contents of the National 
     Drug Control Strategy that involve information properly 
     classified under criteria established by an Executive order 
     shall be presented to Congress separately from the rest of 
     the National Drug Control Strategy.
       ``(C) Selection of data and information.--In selecting data 
     and information for inclusion under subparagraph (A), the 
     Director shall ensure--
       ``(i) the inclusion of data and information that will 
     permit analysis of current trends against previously compiled 
     data and information where the Director believes such 
     analysis enhances long-term assessment of the National Drug 
     Control Strategy; and
       ``(ii) the inclusion of data and information to permit a 
     standardized and uniform assessment of the effectiveness of 
     drug treatment programs in the United States.
       ``(3) Process for development and submission.--In 
     developing and effectively implementing the National Drug 
     Control Strategy, the Director--
       ``(A) shall consult with--
       ``(i) the heads of the National Drug Control Program 
     agencies;
       ``(ii) Congress;
       ``(iii) State, local, and tribal officials;
       ``(iv) private citizens and organizations, including 
     community and faith-based organizations with experience and 
     expertise in demand reduction;
       ``(v) private citizens and organizations with experience 
     and expertise in supply reduction; and
       ``(vi) appropriate representatives of foreign governments;
       ``(B) in satisfying the requirements of subparagraph (A), 
     shall ensure, to the maximum extent possible, that State, 
     local, and tribal officials and relevant private 
     organizations commit to support and take steps to achieve the 
     goals and objectives of the National Drug Control Strategy;
       ``(C) with the concurrence of the Attorney General, may 
     require the El Paso Intelligence Center to undertake specific 
     tasks or projects to support or implement the National Drug 
     Control Strategy; and
       ``(D) with the concurrence of the Director of National 
     Intelligence and the Attorney General, may request that the 
     National Drug Intelligence Center undertake specific tasks or 
     projects to support or implement the National Drug Control 
     Strategy.
       ``(b) Submission of Revised Strategy.--The President may 
     submit to Congress a revised National Drug Control Strategy 
     that meets the requirements of this section--
       ``(1) at any time, upon a determination of the President, 
     in consultation with the Director, that the National Drug 
     Control Strategy in effect is not sufficiently effective; or
       ``(2) if a new President or Director takes office.''.

     SEC. 202. PERFORMANCE MEASUREMENTS.

       Section 706 is amended by adding at the end the following:
       ``(c) Performance Measurement System.--Not later than 
     February 1 of each year, the Director shall submit to 
     Congress as part of the National Drug Control Strategy, a 
     description of a national drug control performance 
     measurement system, that--
       ``(1) develops 2-year and 5-year performance measures and 
     targets for each National Drug Control Strategy goal and 
     objective established for reducing drug use, availability, 
     and the consequences of drug use;
       ``(2) describes the sources of information and data that 
     will be used for each performance measure incorporated into 
     the performance measurement system;
       ``(3) identifies major programs and activities of the 
     National Drug Control Program agencies that support the goals 
     and annual objectives of the National Drug Control Strategy;
       ``(4) evaluates the contribution of demand reduction and 
     supply reduction activities as defined in section 702 
     implemented by each National Drug Control Program agency in 
     support of the National Drug Control Strategy;

[[Page 22882]]

       ``(5) monitors consistency between the drug-related goals 
     and objectives of the National Drug Control Program agencies 
     and ensures that each agency's goals and budgets support and 
     are fully consistent with the National Drug Control Strategy; 
     and
       ``(6) coordinates the development and implementation of 
     national drug control data collection and reporting systems 
     to support policy formulation and performance measurement, 
     including an assessment of--
       ``(A) the quality of current drug use measurement 
     instruments and techniques to measure supply reduction and 
     demand reduction activities;
       ``(B) the adequacy of the coverage of existing national 
     drug use measurement instruments and techniques to measure 
     the illicit drug user population, and groups that are at risk 
     for illicit drug use;
       ``(C) the adequacy of the coverage of existing national 
     treatment outcome monitoring systems to measure the 
     effectiveness of drug abuse treatment in reducing illicit 
     drug use and criminal behavior during and after the 
     completion of substance abuse treatment; and
       ``(D) the actions the Director shall take to correct any 
     deficiencies and limitations identified pursuant to 
     subparagraphs (A) and (B) of this subsection.
       ``(d) Modifications.--A description of any modifications 
     made during the preceding year to the national drug 
     performance measurement system described in subsection (c) 
     shall be included in each report submitted under subsection 
     (b).''.

     SEC. 203. ANNUAL REPORT REQUIREMENT.

       (a) In General.--On or before February 1 of each year, the 
     Director shall submit a report to Congress that describes--
       (1) the strategy of the national media campaign and whether 
     specific objectives of the campaign were accomplished;
       (2) steps taken to ensure that the national media campaign 
     operates in an effective and efficient manner consistent with 
     the overall strategy and focus of the campaign;
       (3) plans to purchase advertising time and space;
       (4) policies and practices implemented to ensure that 
     Federal funds are used responsibly to purchase advertising 
     time and space and eliminate the potential for waste, fraud, 
     and abuse;
       (5) all contracts entered into with a corporation, 
     partnership, or individual working on behalf of the national 
     media campaign;
       (6) specific policies and steps implemented to ensure 
     compliance with title IV of this Act;
       (7) steps taken to ensure that the national media campaign 
     will secure, to the maximum extent possible, no cost matches 
     of advertising time and space or in-kind contributions that 
     are directly related to the campaign in accordance with title 
     IV of this Act; and
       (8) a review and evaluation of the effectiveness of the 
     national media campaign strategy for the past year.
       (b) Audit.--The Government Accountability Office shall, at 
     a frequency of not less than once per year--
       (1) conduct and supervise an audit and investigation 
     relating to the programs and operations of the--
       (A) Office; or
       (B) certain programs within the Office, including--
       (i) the High Intensity Drug Trafficking Areas Program;
       (ii) the Counterdrug Technology Assessment Center; or
       (iii) the National Youth Anti-drug Media Campaign; and
       (2) provide the Director and the appropriate congressional 
     committees with a report containing an evaluation of and 
     recommendations on the--
       (A) policies and activities of the programs and operations 
     subject to the audit and investigation;
       (B) economy, efficiency, and effectiveness in the 
     administration of the reviewed programs and operations; and
       (C) policy or management changes needed to prevent and 
     detect fraud and abuse in such programs and operations.

            TITLE III--HIGH INTENSITY DRUG TRAFFICKING AREAS

     SEC. 301. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

       Section 707 is amended to read as follows:

     ``SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

       ``(a) Establishment.--
       ``(1) In general.--There is established in the Office a 
     program to be known as the High Intensity Drug Trafficking 
     Areas Program (in this section referred to as the `Program').
       ``(2) Purpose.--The purpose of the Program is to reduce 
     drug trafficking and drug production in the United States 
     by--
       ``(A) facilitating cooperation among Federal, State, local, 
     and tribal law enforcement agencies to share information and 
     implement coordinated enforcement activities;
       ``(B) enhancing law enforcement intelligence sharing among 
     Federal, State, local, and tribal law enforcement agencies;
       ``(C) providing reliable law enforcement intelligence to 
     law enforcement agencies needed to design effective 
     enforcement strategies and operations; and
       ``(D) supporting coordinated law enforcement strategies 
     which maximize use of available resources to reduce the 
     supply of illegal drugs in designated areas and in the United 
     States as a whole.
       ``(b) Designation.--
       ``(1) In general.--The Director, in consultation with the 
     Attorney General, the Secretary of the Treasury, the 
     Secretary of Homeland Security, heads of the National Drug 
     Control Program agencies, and the Governor of each applicable 
     State, may designate any specified area of the United States 
     as a high intensity drug trafficking area.
       ``(2) Activities.--After making a designation under 
     paragraph (1) and in order to provide Federal assistance to 
     the area so designated, the Director may--
       ``(A) obligate such sums as are appropriated for the 
     Program;
       ``(B) direct the temporary reassignment of Federal 
     personnel to such area, subject to the approval of the head 
     of the department or agency that employs such personnel;
       ``(C) take any other action authorized under section 704 to 
     provide increased Federal assistance to those areas; and
       ``(D) coordinate activities under this section 
     (specifically administrative, recordkeeping, and funds 
     management activities) with State, local, and tribal 
     officials.
       ``(c) Petitions for Designation.--The Director shall 
     establish regulations under which a coalition of interested 
     law enforcement agencies from an area may petition for 
     designation as a high intensity drug trafficking area. Such 
     regulations shall provide for a regular review by the 
     Director of the petition, including a recommendation 
     regarding the merit of the petition to the Director by a 
     panel of qualified, independent experts.
       ``(d) Factors for Consideration.--In considering whether to 
     designate an area under this section as a high intensity drug 
     trafficking area, the Director shall consider, in addition to 
     such other criteria as the Director considers to be 
     appropriate, the extent to which--
       ``(1) the area is a significant center of illegal drug 
     production, manufacturing, importation, or distribution;
       ``(2) State, local, and tribal law enforcement agencies 
     have committed resources to respond to the drug trafficking 
     problem in the area, thereby indicating a determination to 
     respond aggressively to the problem;
       ``(3) drug-related activities in the area are having a 
     significant harmful impact in the area, and in other areas of 
     the country; and
       ``(4) a significant increase in allocation of Federal 
     resources is necessary to respond adequately to drug-related 
     activities in the area.
       ``(e) Organization of High Intensity Drug Trafficking 
     Areas.--
       ``(1) Executive board and officers.--To be eligible for 
     funds appropriated under this section, each high intensity 
     drug trafficking area shall be governed by an Executive 
     Board. The Executive Board shall designate a chairman, vice 
     chairman, and any other officers to the Executive Board that 
     it determines are necessary.
       ``(2) Responsibilities.--The Executive Board of a high 
     intensity drug trafficking area shall be responsible for--
       ``(A) providing direction and oversight in establishing and 
     achieving the goals of the high intensity drug trafficking 
     area;
       ``(B) managing the funds of the high intensity drug 
     trafficking area;
       ``(C) reviewing and approving all funding proposals 
     consistent with the overall objective of the high intensity 
     drug trafficking area; and
       ``(D) reviewing and approving all reports to the Director 
     on the activities of the high intensity drug trafficking 
     area.
       ``(3) Board representation.--None of the funds appropriated 
     under this section may be expended for any high intensity 
     drug trafficking area, or for a partnership or region of a 
     high intensity drug trafficking area, if the Executive Board 
     for such area, region, or partnership, does not apportion an 
     equal number of votes between representatives of 
     participating Federal agencies and representatives of 
     participating State, local, and tribal agencies. Where it is 
     impractical for an equal number of representatives of Federal 
     agencies and State, local, and tribal agencies to attend a 
     meeting of an Executive Board in person, the Executive Board 
     may use a system of proxy votes or weighted votes to achieve 
     the voting balance required by this paragraph.
       ``(4) No agency relationship.--The eligibility requirements 
     of this section are intended to ensure the responsible use of 
     Federal funds. Nothing in this section is intended to create 
     an agency relationship between individual high intensity drug 
     trafficking areas and the Federal Government.
       ``(f) Use of Funds.--The Director shall ensure that no 
     Federal funds appropriated for the Program are expended for 
     the establishment or expansion of drug treatment programs, 
     and shall ensure that not more than 5 percent of the Federal 
     funds appropriated for the Program are expended for the 
     establishment of drug prevention programs.
       ``(g) Counterterrorism Activities.--
       ``(1) Assistance authorized.--The Director may authorize 
     use of resources available for the Program to assist Federal, 
     State, local,

[[Page 22883]]

     and tribal law enforcement agencies in investigations and 
     activities related to terrorism and prevention of terrorism, 
     especially but not exclusively with respect to such 
     investigations and activities that are also related to drug 
     trafficking.
       ``(2) Limitation.--The Director shall ensure--
       ``(A) that assistance provided under paragraph (1) remains 
     incidental to the purpose of the Program to reduce drug 
     availability and carry out drug-related law enforcement 
     activities; and
       ``(B) that significant resources of the Program are not 
     redirected to activities exclusively related to terrorism, 
     except on a temporary basis under extraordinary 
     circumstances, as determined by the Director.
       ``(h) Role of Drug Enforcement Administration.--The 
     Director, in consultation with the Attorney General, shall 
     ensure that a representative of the Drug Enforcement 
     Administration is included in the Intelligence Support Center 
     for each high intensity drug trafficking area.
       ``(i) Annual HIDTA Program Budget Submissions.--As part of 
     the documentation that supports the President's annual budget 
     request for the Office, the Director shall submit to Congress 
     a budget justification that includes--
       ``(1) the amount proposed for each high intensity drug 
     trafficking area, conditional upon a review by the Office of 
     the request submitted by the HIDTA and the performance of the 
     HIDTA, with supporting narrative descriptions and rationale 
     for each request;
       ``(2) a detailed justification that explains--
       ``(A) the reasons for the proposed funding level; how such 
     funding level was determined based on a current assessment of 
     the drug trafficking threat in each high intensity drug 
     trafficking area;
       ``(B) how such funding will ensure that the goals and 
     objectives of each such area will be achieved; and
       ``(C) how such funding supports the National Drug Control 
     Strategy; and
       ``(3) the amount of HIDTA funds used to investigate and 
     prosecute organizations and individuals trafficking in 
     methamphetamine in the prior calendar year, and a description 
     of how those funds were used.
       ``(j) Emerging Threat Response Fund.--
       ``(1) In general.--Subject to the availability of 
     appropriations, the Director may expend up to 10 percent of 
     the amounts appropriated under this section on a 
     discretionary basis, to respond to any emerging drug 
     trafficking threat in an existing high intensity drug 
     trafficking area, or to establish a new high intensity drug 
     trafficking area or expand an existing high intensity drug 
     trafficking area, in accordance with the criteria established 
     under paragraph (2).
       ``(2) Consideration of impact.--In allocating funds under 
     this subsection, the Director shall consider--
       ``(A) the impact of activities funded on reducing overall 
     drug traffic in the United States, or minimizing the 
     probability that an emerging drug trafficking threat will 
     spread to other areas of the United States; and
       ``(B) such other criteria as the Director considers 
     appropriate.
       ``(k) Evaluation.--
       ``(1) Initial report.--Not later than 90 days after the 
     date of the enactment of this section, the Director shall, 
     after consulting with the Executive Boards of each designated 
     high intensity drug trafficking area, submit a report to 
     Congress that describes, for each designated high intensity 
     drug trafficking area--
       ``(A) the specific purposes for the high intensity drug 
     trafficking area;
       ``(B) the specific long-term and short-term goals and 
     objectives for the high intensity drug trafficking area;
       ``(C) the measurements that will be used to evaluate the 
     performance of the high intensity drug trafficking area in 
     achieving the long-term and short-term goals; and
       ``(D) the reporting requirements needed to evaluate the 
     performance of the high intensity drug trafficking area in 
     achieving the long-term and short-term goals.
       ``(2) Evaluation of hidta program as part of national drug 
     control strategy.--For each designated high intensity drug 
     trafficking area, the Director shall submit, as part of the 
     annual National Drug Control Strategy report, a report that--
       ``(A) describes--
       ``(i) the specific purposes for the high intensity drug 
     trafficking area; and
       ``(ii) the specific long-term and short-term goals and 
     objectives for the high intensity drug trafficking area; and
       ``(B) includes an evaluation of the performance of the high 
     intensity drug trafficking area in accomplishing the specific 
     long-term and short-term goals and objectives identified 
     under paragraph (1)(B).
       ``(l) Assessment of Drug Enforcement Task Forces in High 
     Intensity Drug Trafficking Areas.--Not later than 1 year 
     after the date of enactment of this subsection, and as part 
     of each subsequent annual National Drug Control Strategy 
     report, the Director shall submit to Congress a report--
       ``(1) assessing the number and operation of all federally 
     funded drug enforcement task forces within each high 
     intensity drug trafficking area; and
       ``(2) describing--
       ``(A) each Federal, State, local, and tribal drug 
     enforcement task force operating in the high intensity drug 
     trafficking area;
       ``(B) how such task forces coordinate with each other, with 
     any high intensity drug trafficking area task force, and with 
     investigations receiving funds from the Organized Crime and 
     Drug Enforcement Task Force;
       ``(C) what steps, if any, each such task force takes to 
     share information regarding drug trafficking and drug 
     production with other federally funded drug enforcement task 
     forces in the high intensity drug trafficking area;
       ``(D) the role of the high intensity drug trafficking area 
     in coordinating the sharing of such information among task 
     forces;
       ``(E) the nature and extent of cooperation by each Federal, 
     State, local, and tribal participant in ensuring that such 
     information is shared among law enforcement agencies and with 
     the high intensity drug trafficking area;
       ``(F) the nature and extent to which information sharing 
     and enforcement activities are coordinated with joint 
     terrorism task forces in the high intensity drug trafficking 
     area; and
       ``(G) any recommendations for measures needed to ensure 
     that task force resources are utilized efficiently and 
     effectively to reduce the availability of illegal drugs in 
     the high intensity drug trafficking areas.
       ``(m) Assessment of Law Enforcement Intelligence Sharing in 
     High Intensity Drug Trafficking Areas Program.--Not later 
     than 180 days after the date of the enactment of this 
     section, and as part of each subsequent annual National Drug 
     Control Strategy report, the Director, in consultation with 
     the Director of National Intelligence, shall submit to 
     Congress a report--
       ``(1) evaluating existing and planned law enforcement 
     intelligence systems supported by each high intensity drug 
     trafficking area, or utilized by task forces receiving any 
     funding under the Program, including the extent to which such 
     systems ensure access and availability of law enforcement 
     intelligence to Federal, State, local, and tribal law 
     enforcement agencies within the high intensity drug 
     trafficking area and outside of it;
       ``(2) the extent to which Federal, State, local, and tribal 
     law enforcement agencies participating in each high intensity 
     drug trafficking area are sharing law enforcement 
     intelligence information to assess current drug trafficking 
     threats and design appropriate enforcement strategies; and
       ``(3) the measures needed to improve effective sharing of 
     information and law enforcment intelligence regarding drug 
     trafficking and drug production among Federal, State, local, 
     and tribal law enforcement participating in a high intensity 
     drug trafficking area, and between such agencies and similar 
     agencies outside the high intensity drug trafficking area.
       ``(n) Coordination of Law Enforcement Intelligence Sharing 
     With Organized Crime Drug Enforcement Task Force Program.--
     The Director, in consultation with the Attorney General, 
     shall ensure that any drug enforcement intelligence obtained 
     by the Intelligence Support Center for each high intensity 
     drug trafficking area is shared, on a timely basis, with the 
     drug intelligence fusion center operated by the Organized 
     Crime Drug Enforcement Task Force of the Department of 
     Justice.
       ``(o) Use of Funds To Combat Methamphetamine Trafficking.--
       ``(1) Requirement.--As part of the documentation that 
     supports the President's annual budget request for the 
     Office, the Director shall submit to Congress a report 
     describing the use of HIDTA funds to investigate and 
     prosecute organizations and individuals trafficking in 
     methamphetamine in the prior calendar year.
       ``(2) Contents.--The report shall include--
       ``(A) the number of methamphetamine manufacturing 
     facilities discovered through HIDTA-funded initiatives in the 
     previous fiscal year;
       ``(B) the amounts of methamphetamine or listed chemicals 
     (as that term is defined in section 102(33) of the Controlled 
     Substances Act (21 U.S.C. 802(33)) seized by HIDTA-funded 
     initiatives in the area during the previous year; and
       ``(C) law enforcement intelligence and predictive data from 
     the Drug Enforcement Administration showing patterns and 
     trends in abuse, trafficking, and transportation in 
     methamphetamine and listed chemicals.
       ``(3) Certification.--Before the Director awards any funds 
     to a high intensity drug trafficking area, the Director shall 
     certify that the law enforcement entities participating in 
     that HIDTA are providing laboratory seizure data to the 
     national clandestine laboratory database at the El Paso 
     Intelligence Center.
       ``(p) Authorization of Appropriations.--There is authorized 
     to be appropriated to the Office of National Drug Control 
     Policy to carry out this section--
       ``(1) $240,000,000 for fiscal year 2007;
       ``(2) $250,000,000 for fiscal year 2008;
       ``(3) $260,000,000 for fiscal year 2009;
       ``(4) $270,000,000 for fiscal year 2010; and
       ``(5) $280,000,000 for each of fiscal year 2011.''.

[[Page 22884]]



     SEC. 302. FUNDING FOR CERTAIN HIGH INTENSITY DRUG TRAFFICKING 
                   AREAS.

       (a) Short Title.--This section may be cited as the ``Dawson 
     Family Community Protection Act''.
       (b) Findings.--Congress finds the following:
       (1) In the early morning hours of October 16, 2002, the 
     home of Carnell and Angela Dawson was firebombed in apparent 
     retaliation for Mrs. Dawson's notification to police about 
     persistent drug distribution activity in their East Baltimore 
     City neighborhood.
       (2) The arson claimed the lives of Mr. and Mrs. Dawson and 
     their 5 young children, aged 9 to 14.
       (3) The horrific murder of the Dawson family is a stark 
     example of domestic narco-terrorism.
       (4) In all phases of counternarcotics law enforcement--from 
     prevention to investigation to prosecution to reentry--the 
     voluntary cooperation of ordinary citizens is a critical 
     component.
       (5) Voluntary cooperation is difficult for law enforcement 
     officials to obtain when citizens feel that cooperation 
     carries the risk of violent retaliation by illegal drug 
     trafficking organizations and their affiliates.
       (6) Public confidence that law enforcement is doing all it 
     can to make communities safe is a prerequisite for voluntary 
     cooperation among people who may be subject to intimidation 
     or reprisal (or both).
       (7) Witness protection programs are insufficient on their 
     own to provide security because many individuals and families 
     who strive every day to make distressed neighborhoods livable 
     for their children, other relatives, and neighbors will 
     resist or refuse offers of relocation by local, State, and 
     Federal prosecutorial agencies and because, moreover, the 
     continued presence of strong individuals and families is 
     critical to preserving and strengthening the social fabric in 
     such communities.
       (8) Where (as in certain sections of Baltimore City) 
     interstate trafficking of illegal drugs has severe ancillary 
     local consequences within areas designated as high intensity 
     drug trafficking areas, it is important that supplementary 
     High Intensity Drug Trafficking Areas Program funds be 
     committed to support initiatives aimed at making the affected 
     communities safe for the residents of those communities and 
     encouraging their cooperation with tribal, local, State, and 
     Federal law enforcement efforts to combat illegal drug 
     trafficking.
       (c) Funding for Certain High Intensity Drug Trafficking 
     Areas.--Section 707, as amended by section 301, is amended by 
     adding at the end the following:
       ``(q) Specific Purposes.--
       ``(1) In general.--The Director shall ensure that, of the 
     amounts appropriated for a fiscal year for the Program, at 
     least $7,000,000 is used in high intensity drug trafficking 
     areas with severe neighborhood safety and illegal drug 
     distribution problems.
       ``(2) Required uses.--The funds used under paragraph (1) 
     shall be used--
       ``(A) to ensure the safety of neighborhoods and the 
     protection of communities, including the prevention of the 
     intimidation of potential witnesses of illegal drug 
     distribution and related activities; and
       ``(B) to combat illegal drug trafficking through such 
     methods as the Director considers appropriate, such as 
     establishing or operating (or both) a toll-free telephone 
     hotline for use by the public to provide information about 
     illegal drug-related activities.''.

     SEC. 303. ASSESSMENT.

       The Director shall assess the ability of the HIDTA Program 
     to respond to the so-called ``balloon effect'', whereby urban 
     drug traffickers facing intensive law enforcement efforts 
     expand and spread their trafficking and distribution into 
     rural, suburban, and smaller urban areas by conducting a 
     demonstration project examining the ability of the New York/
     New Jersey HIDTA, with its new single colocated Organized 
     Crime and Drug Enforcement Task Force/High Intensity Drug 
     Trafficking Area Strike Force and HIDTA Regional Intelligence 
     Center, to address the movement of drug traffickers into the 
     more rural, suburban, and smaller areas encompassed by the 
     counties of Albany, Onondaga, Monroe, and Erie in New York 
     State and by annexing these counties into the existing New 
     York/New Jersey HIDTA.

                          TITLE IV--TECHNOLOGY

     SEC. 401. COUNTERDRUG TECHNOLOGY ASSESSMENT CENTER.

       (a) Chief Scientist.--Section 708(b) is amended to read as 
     follows:
       ``(b) Chief Scientist.--There shall be at the head of the 
     Center the Chief Scientist, who shall be appointed by the 
     Director from among individuals qualified and distinguished 
     in the area of science, medicine, engineering, or 
     technology.''.
       (b) Responsibilities.--
       (1) Research and development.--Section 708 is amended by--
       (A) redesignating subsection (d) as subsection (e); and
       (B) striking subsection (c) and inserting the following:
       ``(c) Research and Development Responsibilities.--The 
     Director, acting through the Chief Scientist, shall--
       ``(1) identify and define the short-, medium-, and long-
     term scientific and technological needs of Federal, State, 
     local, and tribal drug supply reduction agencies, including--
       ``(A) advanced surveillance, tracking, and radar imaging;
       ``(B) electronic support measures;
       ``(C) communications;
       ``(D) data fusion, advanced computer systems, and 
     artificial intelligence; and
       ``(E) chemical, biological, radiological (including neutron 
     and electron), and other means of detection;
       ``(2) identify demand reduction basic and applied research 
     needs and initiatives, in consultation with affected National 
     Drug Control Program agencies, including--
       ``(A) improving treatment through neuroscientific advances;
       ``(B) improving the transfer of biomedical research to the 
     clinical setting; and
       ``(C) in consultation with the National Institute of Drug 
     Abuse and the Substance Abuse and Mental Health Services 
     Administration, and through interagency agreements or grants, 
     examining addiction and rehabilitation research and the 
     application of technology to expanding the effectiveness and 
     availability of drug treatment;
       ``(3) make a priority ranking of such needs identified in 
     paragraphs (1) and (2) according to fiscal and technological 
     feasibility, as part of a National Counterdrug Research and 
     Development Program;
       ``(4) oversee and coordinate counterdrug technology 
     initiatives with related activities of other Federal civilian 
     and military departments;
       ``(5) provide support to the development and implementation 
     of the national drug control performance measurement system 
     established under subsection (c) of section 706; and
       ``(6) pursuant to the authority of the Director of National 
     Drug Control Policy under section 704, submit requests to 
     Congress for the reprogramming or transfer of funds 
     appropriated for counterdrug technology research and 
     development.
       ``(d) Limitation on Authority.--The authority granted to 
     the Director under this section shall not extend to the 
     awarding of contracts, management of individual projects, or 
     other operational activities.''.
       (2) Assistance and support.--Subsection (e) of section 708, 
     as redesignated by this section, is amended to read as 
     follows:
       ``(e) Assistance and Support to the Office of National Drug 
     Control Policy.--The Secretary of Defense, the Secretary of 
     Homeland Security, and the Secretary of Health and Human 
     Services shall, to the maximum extent practicable, render 
     assistance and support to the Office and to the Director in 
     the conduct of counterdrug technology assessment.''.
       (3) Technology transfer program.--Section 708 is amended by 
     adding at the end the following:
       ``(f) Technology Transfer Program.--
       ``(1) Program.--The Chief Scientist, with the advice and 
     counsel of experts from State, local, and tribal law 
     enforcement agencies, shall be responsible to the Director 
     for coordination and implementation of a counterdrug 
     technology transfer program.
       ``(2) Purpose.--The purpose of the Technology Transfer 
     Program shall be for the Counterdrug Technology Assessment 
     Center to transfer technology and associated training 
     directly to State, local, and tribal law enforcement 
     agencies.
       ``(3) Priority of receipts.--Transfers shall be made in 
     priority order based on--
       ``(A) the need of potential recipients for such technology;
       ``(B) the effectiveness of the technology to enhance 
     current counterdrug activities of potential recipients; and
       ``(C) the ability and willingness of potential recipients 
     to evaluate transferred technology.
       ``(4) Agreement authority.--The Director may enter into an 
     agreement with the Secretary of Homeland Security to transfer 
     technology with both counterdrug and homeland security 
     applications to State, local, and tribal law enforcement 
     agencies on a reimbursable basis.
       ``(5) Report.--On or before July 1 of each year, the 
     Director shall submit a report to the appropriate 
     congressional committees that addresses the following:
       ``(A) The number of requests received during the previous 
     12 months, including the identity of each requesting agency 
     and the type of technology requested.
       ``(B) The number of requests fulfilled during the previous 
     12 months, including the identity of each recipient agency 
     and the type of technology transferred.
       ``(C) A summary of the criteria used in making the 
     determination on what requests were funded and what requests 
     were not funded, except that such summary shall not include 
     specific information on any individual requests.
       ``(D) A general assessment of the future needs of the 
     program, based on expected changes in threats, expected 
     technologies, and likely need from potential recipients.
       ``(E) An assessment of the effectiveness of the 
     technologies transferred, based in part on the evaluations 
     provided by the recipients, with a recommendation whether the 
     technology should continue to be offered through the 
     program.''.

[[Page 22885]]

       (c) Assistance From Secretary of Homeland Security.--
     Section 708(d) (21 U.S.C. 1707(d)) is amended by inserting 
     ``, the Secretary of Homeland Security,'' after ``The 
     Secretary of Defense''.

                 TITLE V--NATIONAL YOUTH MEDIA CAMPAIGN

     SEC. 501. NATIONAL YOUTH ANTI-DRUG MEDIA CAMPAIGN.

       (a) In General.--Section 709 (21 U.S.C. 1708) is amended to 
     read as follows:

     ``SEC. 709. NATIONAL YOUTH ANTI-DRUG MEDIA CAMPAIGN.

       ``(a) In General.--The Director shall conduct a national 
     youth anti-drug media campaign (referred to in this subtitle 
     as the `national media campaign') in accordance with this 
     section for the purposes of--
       ``(1) preventing drug abuse among young people in the 
     United States;
       ``(2) increasing awareness of adults of the impact of drug 
     abuse on young people; and
       ``(3) encouraging parents and other interested adults to 
     discuss with young people the dangers of illegal drug use.
       ``(b) Use of Funds.--
       ``(1) In general.--Amounts made available to carry out this 
     section for the national media campaign may only be used for 
     the following:
       ``(A) The purchase of media time and space, including the 
     strategic planning for, and accounting of, such purchases.
       ``(B) Creative and talent costs, consistent with paragraph 
     (2)(A).
       ``(C) Advertising production costs.
       ``(D) Testing and evaluation of advertising.
       ``(E) Evaluation of the effectiveness of the national media 
     campaign.
       ``(F) The negotiated fees for the winning bidder on 
     requests for proposals issued either by the Office or its 
     designee to enter into contracts to carry out activities 
     authorized by this section.
       ``(G) Partnerships with professional and civic groups, 
     community-based organizations, including faith-based 
     organizations, and government organizations related to the 
     national media campaign.
       ``(H) Entertainment industry outreach, interactive 
     outreach, media projects and activities, public information, 
     news media outreach, and corporate sponsorship and 
     participation.
       ``(I) Operational and management expenses.
       ``(2) Specific requirements.--
       ``(A) Creative services.--
       ``(i) In using amounts for creative and talent costs under 
     paragraph (1)(B), the Director shall use creative services 
     donated at no cost to the Government (including creative 
     services provided by the Partnership for a Drug-Free America) 
     wherever feasible and may only procure creative services for 
     advertising--

       ``(I) responding to high-priority or emergent campaign 
     needs that cannot timely be obtained at no cost; or
       ``(II) intended to reach a minority, ethnic, or other 
     special audience that cannot reasonably be obtained at no 
     cost; or
       ``(III) the Director determines that the Partnership for a 
     Drug-Free America is unable to provide, pursuant to 
     subsection (d)(2)(B).

       ``(ii) Subject to the availability of appropriations, no 
     more than $1,500,000 may be expended under this section each 
     fiscal year on creative services, except that the Director 
     may expend up to $2,000,000 in a fiscal year on creative 
     services to meet urgent needs of the national media campaign 
     with advance approval from the Committee on Appropriations of 
     the Senate and of the House of Representatives upon a showing 
     of the circumstances causing such urgent needs of the 
     national media campaign.
       ``(B) Testing and evaluation of advertising.--In using 
     amounts for testing and evaluation of advertising under 
     paragraph (1)(D), the Director shall test all advertisements 
     prior to use in the national media campaign to ensure that 
     the advertisements are effective and meet industry-accepted 
     standards. The Director may waive this requirement for 
     advertisements using no more than 10 percent of the purchase 
     of advertising time purchased under this section in a fiscal 
     year and no more than 10 percent of the advertising space 
     purchased under this section in a fiscal year, if the 
     advertisements respond to emergent and time-sensitive 
     campaign needs or the advertisements will not be widely 
     utilized in the national media campaign.
       ``(C) Evaluation of effectiveness of media campaign.--In 
     using amounts for the evaluation of the effectiveness of the 
     national media campaign under paragraph (1)(E), the Director 
     shall--
       ``(i) designate an independent entity to evaluate by April 
     20 of each year the effectiveness of the national media 
     campaign based on data from--

       ``(I) the Monitoring the Future Study published by the 
     Department of Health and Human Services;
       ``(II) the Attitude Tracking Study published by the 
     Partnership for a Drug-Free America;
       ``(III) the National Household Survey on Drug Abuse; and
       ``(IV) other relevant studies or publications, as 
     determined by the Director, including tracking and evaluation 
     data collected according to marketing and advertising 
     industry standards; and

       ``(ii) ensure that the effectiveness of the national media 
     campaign is evaluated in a manner that enables consideration 
     of whether the national media campaign has contributed to 
     reduction of illicit drug use among youth and such other 
     measures of evaluation as the Director determines are 
     appropriate.
       ``(3) Purchase of advertising time and space.--Subject to 
     the availability of appropriations, for each fiscal year, not 
     less than 77 percent of the amounts appropriated under this 
     section shall be used for the purchase of advertising time 
     and space for the national media campaign, subject to the 
     following exceptions:
       ``(A) In any fiscal year for which less than $125,000,000 
     is appropriated for the national media campaign, not less 
     than 72 percent of the amounts appropriated under this 
     section shall be used for the purchase of advertising time 
     and space for the national media campaign.
       ``(B) In any fiscal year for which more than $195,000,000 
     is appropriated under this section, not less than 82 percent 
     shall be used for advertising production costs and the 
     purchase of advertising time and space for the national media 
     campaign.
       ``(c) Advertising.--In carrying out this section, the 
     Director shall ensure that sufficient funds are allocated to 
     meet the stated goals of the national media campaign.
       ``(d) Division of Responsibilities and Functions Under the 
     Program.--
       ``(1) In general.--The Director, in consultation with the 
     Partnership for a Drug-Free America, shall determine the 
     overall purposes and strategy of the national media campaign.
       ``(2) Responsibilities.--
       ``(A) Director.--The Director shall be responsible for 
     implementing a focused national media campaign to meet the 
     purposes set forth in subsection (a), and shall approve--
       ``(i) the strategy of the national media campaign;
       ``(ii) all advertising and promotional material used in the 
     national media campaign; and
       ``(iii) the plan for the purchase of advertising time and 
     space for the national media campaign.
       ``(B) The partnership for a drug-free america.--The 
     Director shall request that the Partnership for a Drug-Free 
     America--
       ``(i) develop and recommend strategies to achieve the goals 
     of the national media campaign, including addressing national 
     and local drug threats in specific regions or States, such as 
     methamphetamine and ecstasy;
       ``(ii) create all advertising to be used in the national 
     media campaign, except advertisements that are--

       ``(I) provided by other nonprofit entities pursuant to 
     subsection (f);
       ``(II) intended to respond to high-priority or emergent 
     campaign needs that cannot timely be obtained at no cost (not 
     including production costs and talent reuse payments), 
     provided that any such advertising material is reviewed by 
     the Partnership for a Drug-Free America;
       ``(III) intended to reach a minority, ethnic, or other 
     special audience that cannot be obtained at no cost (not 
     including production costs and talent reuse payments), 
     provided that any such advertising material is reviewed by 
     the Partnership for a Drug-Free America; or
       ``(IV) any other advertisements that the Director 
     determines that the Partnership for a Drug-Free America is 
     unable to provide or if the Director determines that another 
     entity is more appropriate, subject to the requirements of 
     subsection (b)(2)(A).

     If the Director determines that another entity is more 
     appropriate under clause (ii)(IV), the Director shall notify 
     Congress, through the committees of jurisdiction in the House 
     and Senate, in writing, not less than 30 days prior to 
     contracting with a party other than the Partnership for a 
     Drug-Free America.
       ``(C) Media buying contractor.--The Director shall enter 
     into a contract with a media buying contractor to plan and 
     purchase advertising time and space for the national media 
     campaign. The media buying contractor shall not provide any 
     other service or material, or conduct any other function or 
     activity which the Director determines should be provided by 
     the Partnership for a Drug-Free America.
       ``(e) Prohibitions.--None of the amounts made available 
     under subsection (b) may be obligated or expended for any of 
     the following:
       ``(1) To supplant current anti-drug community-based 
     coalitions.
       ``(2) To supplant pro bono public service time donated by 
     national and local broadcasting networks for other public 
     service campaigns.
       ``(3) For partisan political purposes, or express advocacy 
     in support of or to defeat any clearly identified candidate, 
     clearly identified ballot initiative, or clearly identified 
     legislative or regulatory proposal.
       ``(4) To fund advertising that features any elected 
     officials, persons seeking elected office, cabinet level 
     officials, or other Federal officials employed pursuant to 
     section 213 of Schedule C of title 5, Code of Federal 
     Regulations.

[[Page 22886]]

       ``(5) To fund advertising that does not contain a primary 
     message intended to reduce or prevent illicit drug use.
       ``(6) To fund advertising containing a primary message 
     intended to promote support for the media campaign or private 
     sector contributions to the media campaign.
       ``(f) Matching Requirement.--
       ``(1) In general.--Amounts made available under subsection 
     (b) for media time and space shall be matched by an equal 
     amount of non-Federal funds for the national media campaign, 
     or be matched with in-kind contributions of the same value.
       ``(2) No-cost match advertising direct relationship 
     requirement.--The Director shall ensure that at least 70 
     percent of no-cost match advertising provided directly 
     relates to substance abuse prevention consistent with the 
     specific purposes of the national media campaign, except that 
     in any fiscal year in which less than $125,000,000 is 
     appropriated to the national media campaign, the Director 
     shall ensure that at least 85 percent of no-cost match 
     advertising directly relates to substance abuse prevention 
     consistent with the specific purposes of the national media 
     campaign.
       ``(3) No-cost match advertising not directly related.--The 
     Director shall ensure that no-cost match advertising that 
     does not directly relate to substance abuse prevention 
     consistent with the purposes of the national media campaign 
     includes a clear anti-drug message. Such message is not 
     required to be the primary message of the match advertising.
       ``(g) Financial and Performance Accountability.--The 
     Director shall cause to be performed--
       ``(1) audits and reviews of costs of the national media 
     campaign pursuant to section 304C of the Federal Property and 
     Administrative Services Act of 1949 (41 U.S.C. 254d); and
       ``(2) an audit to determine whether the costs of the 
     national media campaign are allowable under section 306 of 
     such Act (41 U.S.C. 256).
       ``(h) Report to Congress.--The Director shall submit on an 
     annual basis a report to Congress that describes--
       ``(1) the strategy of the national media campaign and 
     whether specific objectives of the media campaign were 
     accomplished;
       ``(2) steps taken to ensure that the national media 
     campaign operates in an effective and efficient manner 
     consistent with the overall strategy and focus of the 
     national media campaign;
       ``(3) plans to purchase advertising time and space;
       ``(4) policies and practices implemented to ensure that 
     Federal funds are used responsibly to purchase advertising 
     time and space and eliminate the potential for waste, fraud, 
     and abuse; and
       ``(5) all contracts entered into with a corporation, 
     partnership, or individual working on behalf of the national 
     media campaign.
       ``(i) Local Target Requirement.--The Director shall, to the 
     maximum extent feasible, use amounts made available under 
     this section for media that focuses on, or includes specific 
     information on, prevention or treatment resources for 
     consumers within specific local areas.
       ``(j) Prevention of Marijuana Use.--
       ``(1) Findings.--The Congress finds the following:
       ``(A) 60 percent of adolescent admissions for drug 
     treatment are based on marijuana use.
       ``(B) Potency levels of contemporary marijuana, 
     particularly hydroponically grown marijuana, are 
     significantly higher than in the past, rising from under 1 
     percent of THC in the mid-1970s to as high as 30 percent 
     today.
       ``(C) Contemporary research has demonstrated that youths 
     smoking marijuana early in life may be up to 5 times more 
     likely to use hard drugs.
       ``(D) Contemporary research has demonstrated clear 
     detrimental effects in adolescent educational achievement 
     resulting from marijuana use.
       ``(E) Contemporary research has demonstrated clear 
     detrimental effects in adolescent brain development resulting 
     from marijuana use.
       ``(F) An estimated 9,000,000 Americans a year drive while 
     under the influence of illegal drugs, including marijuana.
       ``(G) Marijuana smoke contains 50 to 70 percent more of 
     certain cancer causing chemicals than tobacco smoke.
       ``(H) Teens who use marijuana are up to 4 times more likely 
     to have a teen pregnancy than teens who have not.
       ``(I) Federal law enforcement agencies have identified 
     clear links suggesting that trade in hydroponic marijuana 
     facilitates trade by criminal organizations in hard drugs, 
     including heroin.
       ``(J) Federal law enforcement agencies have identified 
     possible links between trade in cannabis products and 
     financing for terrorist organizations.
       ``(2) Emphasis on prevention of youth marijuana use.--In 
     conducting advertising and activities otherwise authorized 
     under this section, the Director may emphasize prevention of 
     youth marijuana use.
       ``(k) Prevention of Methamphetamine Abuse and Other 
     Emerging Drug Abuse Threats.--
       ``(1) Requirement to use 10 percent of funds for 
     methamphetamine abuse prevention.--The Director shall ensure 
     that, of the amounts appropriated under this section for the 
     national media campaign for a fiscal year, not less than 10 
     percent shall be expended solely for the activities described 
     subsection (b)(1) with respect to advertisements specifically 
     intended to reduce the use of methamphetamine.
       ``(2) Authority to use funds for other drug abuse upon 
     certification that methamphetamine abuse fell during fiscal 
     year 2007.--With respect to fiscal year 2008 and any fiscal 
     year thereafter, if the Director certifies in writing to 
     Congress that domestic methamphetamine laboratory seizures 
     (as reported to the El Paso Intelligence Center of the Drug 
     Enforcement Administration) decreased to at least 75 percent 
     of the 2006 level, or the Director has documented a highly, 
     statistically significant increase in a specific drug, from a 
     baseline determined by locally collected data, that can be 
     defined as a local drug crisis, the Director may apply 
     paragraph (1)(A) for that fiscal year with respect to 
     advertisements specifically intended to reduce the use of 
     such other drugs.
       ``(l) Authorization of Appropriations.--There is authorized 
     to be appropriated to the Office to carry out this section, 
     $195,000,000 for each of fiscal years 2007 and 2008 and 
     $210,000,000 for each of fiscal years 2009 through 2011.''.
       (b) Repeal of Superseded Provisions.--The Drug-Free Media 
     Campaign Act of 1998 (21 U.S.C. 1801 et seq.) is repealed.

       TITLE VI--AUTHORIZATIONS AND EXTENSION OF TERMINATION DATE

     SEC. 601. AUTHORIZATION OF APPROPRIATIONS.

       Section 714 is amended--
       (1) by striking ``title,'' and inserting ``title except 
     activities otherwise specified,''; and
       (2) by striking ``1999 through 2003'' and inserting ``2006 
     through 2010''.

     SEC. 602. EXTENSION OF TERMINATION DATE.

       Section 715(a) is amended by striking ``September 30, 2003, 
     this title and the amendments made by this title'' and 
     inserting ``September 30, 2010, this title and the amendments 
     made to this title''.

                     TITLE VII--ANTI-DOPING AGENCY

     SEC. 701. DESIGNATION OF UNITED STATES ANTI-DOPING AGENCY.

       (a) Definitions.--In this title:
       (1) United states olympic committee.--The term ``United 
     States Olympic Committee'' means the organization established 
     by the ``Ted Stevens Olympic and Amateur Sports Act'' (36 
     U.S.C. 220501 et seq.).
       (2) Amateur athletic competition.--The term ``amateur 
     athletic competition'' means a contest, game, meet, match, 
     tournament, regatta, or other event in which amateur athletes 
     compete (36 U.S.C. 220501(b)(2)).
       (3) Amateur athlete.--The term ``amateur athlete'' means an 
     athlete who meets the eligibility standards established by 
     the national governing body or paralympic sports organization 
     for the sport in which the athlete competes (36 U.S.C. 
     22501(b)(1)).
       (4) Gene doping.--The term ``gene doping'' means the 
     nontherapeutic use of cells, genes, genetic elements, or of 
     the modulation of gene expression, having the capacity to 
     enhance athletic performance.
       (b) In General.--The United States Anti-Doping Agency 
     shall--
       (1) serve as the independent anti-doping organization for 
     the amateur athletic competitions recognized by the United 
     States Olympic Committee;
       (2) ensure that athletes participating in amateur athletic 
     activities recognized by the United States Olympic Committee 
     are prevented from using performance-enhancing drugs, or 
     performance-enhancing genetic modifications accomplished 
     through gene-doping;
       (3) implement anti-doping education, research, testing, and 
     adjudication programs to prevent United States Amateur 
     Athletes participating in any activity recognized by the 
     United States Olympic Committee from using performance-
     enhancing drugs, or performance-enhancing genetic 
     modifications accomplished through gene-doping;
       (4) serve as the United States representative responsible 
     for coordination with other anti-doping organizations 
     coordinating amateur athletic competitions recognized by the 
     United States Olympic Committee to ensure the integrity of 
     athletic competition, the health of the athletes and the 
     prevention of use of performance-enhancing drugs, or 
     performance-enhancing genetic modifications accomplished 
     through gene-doping by United States amateur athletes; and
       (5) permanently include ``gene doping'' among any list of 
     prohibited substances adopted by the Agency.

     SEC. 702. RECORDS, AUDIT, AND REPORT.

       (a) Records.--The United States Anti-Doping Agency shall 
     keep correct and complete records of account.
       (b) Report.--The United States Anti-Doping Agency shall 
     submit an annual report to Congress which shall include--
       (1) an audit conducted and submitted in accordance with 
     section 10101 of title 36, United States Code; and
       (2) a description of the activities of the agency.

     SEC. 703. AUTHORIZATION OF APPROPRIATIONS.

       There are authorized to be appropriated to the United 
     States Anti-Doping Agency--

[[Page 22887]]

       (1) for fiscal year 2007, $9,700,000;
       (2) for fiscal year 2008, $10,300,000;
       (3) for fiscal year 2009, $10,600,000;
       (4) for fiscal year 2010, $11,000,000; and
       (5) for fiscal year 2011, $11,500,000.

                   TITLE VIII--DRUG-FREE COMMUNITIES

     SEC. 801. REAUTHORIZATION.

       (a) In General.--Section 1024(a) of the Drug-Free 
     Communities Act of 1997 (21 U.S.C. 1524(a)) is amended--
       (1) in paragraph (9), by striking ``and'' after the 
     semicolon;
       (2) in paragraph (10), by striking the period and inserting 
     a semicolon; and
       (3) by adding at the end the following:
       ``(11) $109,000,000 for fiscal year 2008;
       ``(12) $114,000,000 for fiscal year 2009;
       ``(13) $119,000,000 for fiscal year 2010;
       ``(14) $124,000,000 for fiscal year 2011; and
       ``(15) $129,000,000 for fiscal year 2012.''.
       (b) Administration Costs.--Section 1024(b) of the Drug-Free 
     Communities Act of 1997 (21 U.S.C. 1524(b)) is amended to 
     read as follows:
       ``(b) Administrative Costs.--
       ``(1) Limitation.--Not more than 3 percent of the funds 
     appropriated for this chapter may be used by the Office of 
     National Control Policy to pay for administrative costs 
     associated with their responsibilities under the chapter.
       ``(2) Designated agency.--The agency delegated to carry out 
     this program under section 1031(d) may use up to 5 percent of 
     the funds allocated for grants under this chapter for 
     administrative costs associated with carrying out the 
     program.''.

     SEC. 802. SUSPENSION OF GRANTS.

       (a) In General.--Section 1032(b) of the Drug-Free 
     Communities Act of 1997 (21 U.S.C. 1532(b)) is amended by 
     adding at the end the following:
       ``(4) Process for suspension.--A grantee shall not be 
     suspended or terminated under paragraph (1)(A)(ii), 
     (2)(A)(iii), or (3)(E) unless that grantee is afforded a 
     fair, timely, and independent appeal prior to such suspension 
     or termination.''.
       (b) Report to Congress.--Not later than 60 days after the 
     date of enactment of this Act, the Director of the Office of 
     National Drug Control Policy shall submit to Congress a 
     report detailing the appeals process required by section 
     1032(b)(4) of the Drug-Free Communities Act of 1997, as added 
     by subsection (a).

     SEC. 803. GRANT AWARD INCREASE.

       Subsections (b)(1)(A)(iv), (b)(2)(C)(i), and (b)(3)(F) of 
     section 1032 of the Drug-Free Communities Act of 1997 (21 
     U.S.C. 1532) are amended by striking ``$100,000'' and 
     inserting ``$125,000''.

     SEC. 804. PROHIBITION ON ADDITIONAL ELIGIBILITY CRITERIA.

       Section 1032(a) of the Drug-Free Communities Act of 1997 
     (21 U.S.C. 1532(a)) is amended by adding at the end the 
     following:
       ``(7) Additional criteria.--The Director shall not impose 
     any eligibility criteria on new applicants or renewal 
     grantees not provided in this chapter.''.

     SEC. 805. NATIONAL COMMUNITY ANTI-DRUG COALITION INSTITUTE.

       Section 4 of Public Law 107-82 (21 U.S.C. 1521 note), 
     reauthorizing the Drug-Free Communities Support Program, is 
     amended--
       (1) by amending subsection (a) to read as follows:
       ``(a) In General.--The Director of the Office of National 
     Drug Control Policy shall, using amounts authorized to be 
     appropriated by subsection (d), make a directed grant to 
     Community Anti-Drug Coalitions of America to provide for the 
     continuation of the National Community Anti-drug Coalition 
     Institute.'';
       (2) by striking subsection (b) and redesignating 
     subsections (c) and (d) as (b) and (c), respectively; and
       (3) in subsection (c), as redesignated by paragraph (2), by 
     adding at the end the following:
       ``(4) For each of the fiscal years 2008 through 2012, 
     $2,000,000.''.

              TITLE IX--NATIONAL GUARD COUNTERDRUG SCHOOLS

     SEC. 901. NATIONAL GUARD COUNTERDRUG SCHOOLS.

       (a) Authority To Operate.--Under such regulations as the 
     Secretary of Defense may prescribe, the Chief of the National 
     Guard Bureau may establish and operate, or provide financial 
     assistance to the States to establish and operate, not more 
     than 5 schools (to be known generally as ``National Guard 
     counterdrug schools'').
       (b) Purpose.--The purpose of the National Guard counterdrug 
     schools shall be the provision by the National Guard of 
     training in drug interdiction and counterdrug activities and 
     drug demand reduction activities to personnel of the 
     following:
       (1) Federal agencies.
       (2) State, local, and tribal law enforcement agencies.
       (3) Community-based organizations engaged in such 
     activities.
       (4) Other non-Federal governmental and private entities and 
     organizations engaged in such activities.
       (c) Counterdrug Schools Specified.--The National Guard 
     counterdrug schools operated under the authority in 
     subsection (a) are as follows:
       (1) The National Interagency Civil-Military Institute 
     (NICI), San Luis Obispo, California.
       (2) The Multi-Jurisdictional Counterdrug Task Force 
     Training (MCTFT), St. Petersburg, Florida.
       (3) The Midwest Counterdrug Training Center (MCTC), 
     Johnston, Iowa.
       (4) The Regional Counterdrug Training Academy (RCTA), 
     Meridian, Mississippi.
       (5) The Northeast Regional Counterdrug Training Center 
     (NCTC), Fort Indiantown Gap, Pennsylvania.
       (d) Use of National Guard Personnel.--
       (1) In general.--To the extent provided for in the State 
     drug interdiction and counterdrug activities plan of a State 
     in which a National Guard counterdrug school is located, 
     personnel of the National Guard of that State who are ordered 
     to perform full-time National Guard duty authorized under 
     section 112(b) of that title 32, United States Code, may 
     provide training referred to in subsection (b) at that 
     school.
       (2) Definition.--In this subsection, the term ``State drug 
     interdiction and counterdrug activities plan'', in the case 
     of a State, means the current plan submitted by the Governor 
     of the State to the Secretary of Defense under section 112 of 
     title 32, United States Code.
       (e) Treatment Under Authority To Provide Counterdrug 
     Support.--The provisions of section 1004 of the National 
     Defense Authorization Act for Fiscal Year 1991 (Public Law 
     101-510; 10 U.S.C. 374 note) shall apply to any activities of 
     a National Guard counterdrug school under this section that 
     are for an agency referred to in subsection (a) of such 
     section 1004 and for a purpose set forth in subsection (b) of 
     such section 1004.
       (f) Annual Reports on Activities.--
       (1) In general.--Not later than February 1 each year, the 
     Secretary of Defense shall submit to Congress a report on the 
     activities of the National Guard counterdrug schools during 
     the preceding year.
       (2) Contents.--Each report under paragraph (1) shall set 
     forth the following:
       (A) Funding.--The amount made available for each National 
     Guard counterdrug school during the fiscal year ending in the 
     year preceding the year in which such report is submitted.
       (B) Activities.--A description of the activities of each 
     National Guard counterdrug school during the year preceding 
     the year in which such report is submitted.
       (g) Authorization of Appropriations.--
       (1) In general.--There is hereby authorized to be 
     appropriated for the Department of Defense for the National 
     Guard for each of fiscal years 2006 through 2010, $30,000,000 
     for purposes of the National Guard counterdrug schools in 
     such fiscal year.
       (2) Construction.--The amount authorized to be appropriated 
     by paragraph (1) for a fiscal year is in addition to any 
     other amount authorized to be appropriated for the Department 
     of Defense for the National Guard for such fiscal year.

TITLE X--NATIONAL METHAMPHETAMINE INFORMATION CLEARINGHOUSE ACT OF 2006

     SEC. 1001. SHORT TITLE.

       This title may be cited as the ``National Methamphetamine 
     Information Clearinghouse Act of 2006''.

     SEC. 1002. DEFINITIONS.

       In this title--
       (1) the term ``Council'' means the National Methamphetamine 
     Advisory Council established under section 1003(b)(1);
       (2) the term ``drug endangered children'' means children 
     whose physical, mental, or emotional health are at risk 
     because of the production, use, or other effects of 
     methamphetamine production or use by another person;
       (3) the term ``National Methamphetamine Information 
     Clearinghouse'' or ``NMIC'' means the information 
     clearinghouse established under section 1003(a); and
       (4) the term ``qualified entity'' means a State, local, or 
     tribal government, school board, or public health, law 
     enforcement, nonprofit, community anti-drug coalition, or 
     other nongovernmental organization providing services related 
     to methamphetamines.

     SEC. 1003. ESTABLISHMENT OF CLEARINGHOUSE AND ADVISORY 
                   COUNCIL.

       (a) Clearinghouse.--There is established, under the 
     supervision of the Attorney General of the United States, an 
     information clearinghouse to be known as the National 
     Methamphetamine Information Clearinghouse.
       (b) Advisory Council.--
       (1) In general.--There is established an advisory council 
     to be known as the National Methamphetamine Advisory Council.
       (2) Membership.--The Council shall consist of 10 members 
     appointed by the Attorney General--
       (A) not fewer than 3 of whom shall be representatives of 
     law enforcement agencies;
       (B) not fewer than 4 of whom shall be representatives of 
     nongovernmental and nonprofit organizations providing 
     services or training and implementing programs or strategies 
     related to methamphetamines; and
       (C) 1 of whom shall be a representative of the Department 
     of Health and Human Services.
       (3) Period of appointment; vacancies.--Members shall be 
     appointed for 3 years. Any

[[Page 22888]]

     vacancy in the Council shall not affect its powers, but shall 
     be filled in the same manner as the original appointment.
       (4) Personnel matters.--
       (A) Travel expenses.--The members of the Council shall be 
     allowed travel expenses, including per diem in lieu of 
     subsistence, at rates authorized for employees of agencies 
     under subchapter I of chapter 57 of title 5, United States 
     Code, while away from their homes or regular places of 
     business in the performance of services for the Council.
       (B) No compensation.--The members of the Council shall not 
     receive compensation for the performance of the duties of a 
     member of the Council.

     SEC. 1004. NMIC REQUIREMENTS AND REVIEW.

       (a) In General.--The NMIC shall promote sharing information 
     regarding successful law enforcement, treatment, 
     environmental, prevention, social services, and other 
     programs related to the production, use, or effects of 
     methamphetamine and grants available for such programs.
       (b) Components.--The NMIC shall include--
       (1) a toll-free number; and
       (2) a website that provides a searchable database, which--
       (A) provides information on the short-term and long-term 
     effects of methamphetamine use;
       (B) provides information regarding methamphetamine 
     treatment and prevention programs and strategies and programs 
     for drug endangered children, including descriptions of 
     successful programs and strategies and contact information 
     for such programs and strategies;
       (C) provides information regarding grants for 
     methamphetamine-related programs, including contact 
     information and links to websites;
       (D) allows a qualified entity to submit items to be posted 
     on the website regarding successful public or private 
     programs or other useful information related to the 
     production, use, or effects of methamphetamine;
       (E) includes a restricted section that may only be accessed 
     by a law enforcement organization that contains successful 
     strategies, training techniques, and other information that 
     the Council determines helpful to law enforcement agency 
     efforts to identify or combat the production, use or effects 
     of methamphetamine;
       (F) allows public access to all information not in a 
     restricted section; and
       (G) contains any additional information the Council 
     determines may be useful in identifying or combating the 
     production, use, or effects of methamphetamine.
     Thirty days after the website in paragraph (2) is 
     operational, no funds shall be expended to continue the 
     website methresources.gov.
       (c) Review of Posted Information.--
       (1) In general.--Not later than 30 days after the date of 
     submission of an item by a qualified entity, the Council 
     shall review an item submitted for posting on the website 
     described in subsection (b)(2)--
       (A) to evaluate and determine whether the item, as 
     submitted or as modified, meets the requirements for posting; 
     and
       (B) in consultation with the Attorney General, to determine 
     whether the item should be posted in a restricted section of 
     the website.
       (2) Determination.--Not later than 45 days after the date 
     of submission of an item, the Council shall--
       (A) post the item on the website described in subsection 
     (b)(2); or
       (B) notify the qualified entity that submitted the item 
     regarding the reason such item shall not be posted and 
     modifications, if any, that the qualified entity may make to 
     allow the item to be posted.

     SEC. 1005. AUTHORIZATION OF APPROPRIATIONS.

       There are authorized to be appropriated--
       (1) for fiscal year 2007--
       (A) $500,000 to establish the NMIC and Council; and
       (B) such sums as are necessary for the operation of the 
     NMIC and Council; and
       (2) for each of fiscal years 2008 and 2009, such sums as 
     are necessary for the operation of the NMIC and Council.

                   TITLE XI--MISCELLANEOUS PROVISIONS

     SEC. 1101. REPEALS.

       (a) Act.--Section 710 is repealed.
       (b) Forfeiture Assets.--Section 6073 of the Assets 
     Forfeiture Amendments Act of 1988 (21 U.S.C. 1509) is 
     repealed.

     SEC. 1102. CONTROLLED SUBSTANCES ACT AMENDMENTS.

       Section 303(g)(2) of the Controlled Substances Act (21 
     U.S.C. 823(g)(2)) is amended--
       (1) in subparagraph (B)(iii), by striking ``except that 
     the'' and inserting the following: ``unless, not sooner than 
     1 year after the date on which the practitioner submitted the 
     initial notification, the practitioner submits a second 
     notification to the Secretary of the need and intent of the 
     practitioner to treat up to 100 patients. A second 
     notification under this clause shall contain the 
     certifications required by clauses (i) and (ii) of this 
     subparagraph. The''; and
       (2) in subparagraph (J)--
       (A) in clause (i), by striking ``thereafter'' and all that 
     follows through the period and inserting ``thereafter.'';
       (B) in clause (ii), by striking ``Drug Addiction Treatment 
     Act of 2000'' and inserting ``Office of National Drug Control 
     Policy Reauthorization Act of 2006''; and
       (C) in clause (iii), by striking ``this paragraph should 
     not remain in effect, this paragraph ceases to be in effect'' 
     and inserting ``subparagraph (B)(iii) should be applied by 
     limiting the total number of patients a practitioner may 
     treat to 30, then the provisions in such subparagraph 
     (B)(iii) permitting more than 30 patients shall not apply, 
     effective''.

     SEC. 1103. REPORT ON LAW ENFORCEMENT INTELLIGENCE SHARING.

       Not later than 180 days after the date of enactment of this 
     Act, the Director shall submit to Congress a report--
       (1) evaluating existing and planned law enforcement 
     intelligence systems used by Federal, State, local, and 
     tribal law enforcement agencies responsible for drug 
     trafficking and drug production enforcement; and
       (2) addressing--
       (A) the current law enforcement intelligence systems used 
     by Federal, State, local, and tribal law enforcement 
     agencies;
       (B) the compatibility of such systems in ensuring access 
     and availability of law enforcement intelligence to Federal, 
     State, local, and tribal law enforcement;
       (C) the extent to which Federal, State, local, and tribal 
     law enforcement are sharing law enforcement intelligence 
     information to assess current threats and design appropriate 
     enforcement strategies; and
       (D) the measures needed to ensure and to promote effective 
     information sharing among law enforcement intelligence 
     systems operated by Federal, State, local, and tribal law 
     enforcement agencies responsible for drug trafficking and 
     drug production enforcement.

     SEC. 1104. REQUIREMENT FOR SOUTH AMERICAN HEROIN STRATEGY.

       (a) In General.--Not later than 90 days after the date of 
     enactment of this Act, the Director, in coordination with the 
     Secretary of State, shall submit to Congress a comprehensive 
     strategy that addresses the increased threat from South 
     American heroin, and in particular Colombian heroin, and the 
     emerging threat from opium poppy grown in Peru and often 
     intended for transit to Columbia for processing into heroin.
       (b) Contents.--The strategy submitted under subsection (a) 
     shall include--
       (1) opium eradication efforts to eliminate the problem at 
     the source to prevent heroin from entering the stream of 
     commerce;
       (2) interdiction and precursor chemical controls;
       (3) demand reduction and treatment;
       (4) alternative development programs, including direct 
     assistance to regional governments to demobilize and provide 
     alternative livelihoods to former members of insurgent or 
     other groups engaged in heroin, cocoa, or other illicit drug 
     production or trafficking;
       (5) efforts to inform and involve local citizens in the 
     programs described in paragraphs (1) through (4), such as 
     through leaflets advertising rewards for information; and
       (6) an assessment of the specific level of funding and 
     resources necessary to simultaneously address the threat from 
     South American heroin and the threat from Colombian and 
     Peruvian coca.
       (c) Treatment of Classified or Law Enforcement Sensitive 
     Information.--Any content of the strategy submitted under 
     subsection (a) that involves information classified under 
     criteria established by an Executive order, or whose public 
     disclosure, as determined by the Director or the head of any 
     relevant Federal agency, would be detrimental to the law 
     enforcement of national security activities of any Federal, 
     foreign, or international agency, shall be presented to 
     Congress separately from the rest of the strategy.

     SEC. 1105. MODEL ACTS.

       (a) In General.--The Director of the Office of National 
     Drug Control Policy shall provide for or shall enter into an 
     agreement with a non-profit corporation that is described in 
     section 501(c)(3) of the Internal Revenue Code of 1986 and 
     exempt from tax under section 501(a) of such Code to--
       (1) advise States on establishing laws and policies to 
     address alcohol and other drug issues, based on the model 
     State drug laws developed by the President's Commission on 
     Model State Drug Laws in 1993; and
       (2) revise such model State drug laws and draft 
     supplementary model State laws to take into consideration 
     changes in the alcohol and drug abuse problems in the State 
     involved.
       (b) Authorization of Appropriations.--There is authorized 
     to be appropriated to carry out this subsection $1,500,000 
     for each of fiscal years 2007 through 2011.

     SEC. 1106. STUDY ON IATROGENIC ADDICTION ASSOCIATED WITH 
                   PRESCRIPTION OPIOID ANALGESIC DRUGS.

       (a) In General.--
       (1) Study.--The Director of the Office of National Drug 
     Control Policy shall request the Institute of Medicine of the 
     National Academy of Sciences to enter into an agreement under 
     which the Institute agrees to study certain aspects of 
     iatrogenic addiction to prescription opioid analgesics 
     included in schedules II and III of the Controlled Substances 
     Act (21 U.S.C. 812).
       (2) Iatrogenic addiction.--In this section, the term 
     ``iatrogenic addiction'' means an

[[Page 22889]]

     addiction developed from the use of an opioid analgesic by an 
     individual with no previous history of any addiction, who has 
     lawfully obtained and used the drug for a legitimate medical 
     purpose by administration from, or pursuant to the 
     prescription or order of, an individual practitioner acting 
     in the usual course of professional practice.
       (b) Requirements.--The study conducted pursuant to this 
     section shall assess the current scientific literature to 
     determine, if possible--
       (1) the rate of iatrogenic addiction associated with the 
     appropriate use of prescription drugs described in subsection 
     (a);
       (2) the impact of iatrogenic addiction associated with the 
     appropriate use of prescription drugs described in subsection 
     (a) on the individual, the prescriber, other patients, and 
     society in general;
       (3) the comparative abuse liability of prescription drugs 
     described in subsection (a) when used properly by the 
     ultimate user for a legitimate medical purpose; and
       (4)(A) what types of prospective or retrospective studies 
     should be undertaken to determine the rate of iatrogenic 
     addiction associated with the appropriate use of the 
     prescription drugs described in subsection (a); and
       (B) a feasible timeline for conducting and reporting such 
     studies, should the current state of the scientific 
     literature be insufficient to determine the rate, impact, and 
     comparative abuse liability of prescription drugs described 
     in subsection (a).
       (c) Report.--Not later than 1 year after the date of 
     enactment of this Act, the Director of the Office of National 
     Drug Control Policy shall ensure that the agreement under 
     subsection (a) provides for the submission of a report to the 
     Congress on the status of the study conducted pursuant to 
     this section.

     SEC. 1107. REQUIREMENT FOR STRATEGY TO STOP INTERNET 
                   ADVERTISING OF PRESCRIPTION MEDICINES WITHOUT A 
                   PRESCRIPTION.

       Not later than 120 days after the date of the enactment of 
     this Act, the Director of the Office of National Drug Control 
     Policy shall submit to Congress a strategy to stop 
     advertisements that provide information about obtaining over 
     the Internet drugs (as defined in section 702(3) of the 
     Office of National Drug Control Policy Reauthorization Act of 
     1998) for which a prescription is required without the use of 
     such a lawful prescription.

     SEC. 1108. REQUIREMENT FOR STUDY ON DIVERSION AND 
                   INAPPROPRIATE USES OF PRESCRIPTION DRUGS.

       Not later than 90 days after the date of enactment of this 
     Act, the Director of the Office of National Drug Control 
     Policy, in consultation with the Secretary of Health and 
     Human Services, shall submit to Congress a report that 
     includes a plan to conduct a study on the illegal diversion 
     and inappropriate uses of prescription drugs, including the 
     following:
       (1) Methods to utilize both public use surveys that are in 
     existence as of the date of enactment of this Act and other 
     surveys to provide appropriate baseline data on the natural 
     history of diversion and abuse of prescription drugs that are 
     included in schedules under the Controlled Substances Act to 
     evaluate the extent and nature of potential problems with 
     such use to guide corrective actions which may reduce such 
     problems without unintentionally hindering access to these 
     drugs for legitimate medical purposes. Specifically, other 
     surveys to be considered are those that address the abuse of 
     these substances on a regional or national basis, and those 
     that address the diversion of these substances on a regional 
     or national basis.
       (2) A scientifically based analysis of the relative 
     contribution of both innate and acquired genetic factors, 
     environmental factors, psychological factors, and drug 
     characteristics that contribute to addiction to prescription 
     drugs.

     SEC. 1109. REQUIREMENT FOR AFGHAN HEROIN STRATEGY.

       (a) In General.--Not later than 90 days after the date of 
     the enactment of this Act, the Director of the Office of 
     National Drug Control Policy shall submit to the Congress a 
     comprehensive strategy that addresses the increased threat 
     from Afghan heroin.
       (b) Contents.--The strategy shall include--
       (1) opium crop eradication efforts to eliminate the problem 
     at the source to prevent heroin from entering the stream of 
     commerce;
       (2) destruction or other direct elimination of stockpiles 
     of heroin and raw opium, and heroin production and storage 
     facilities;
       (3) interdiction and precursor chemical controls;
       (4) demand reduction and treatment;
       (5) alternative development programs;
       (6) measures to improve cooperation and coordination 
     between Federal Government agencies, and between such 
     agencies, agencies of foreign governments, and international 
     organizations with responsibility for the prevention of 
     heroin production in, or trafficking out of, Afghanistan; and
       (7) an assessment of the specific level of funding and 
     resources necessary significantly to reduce the production 
     and trafficking of heroin.
       (c) Treatment of Classified or Law Enforcement Sensitive 
     Information.--Any content of the strategy that involves 
     information classified under criteria established by an 
     Executive order, or whose public disclosure, as determined by 
     the Director or the head of any relevant Federal agency, 
     would be detrimental to the law enforcement or national 
     security activities of any Federal, foreign, or international 
     agency, shall be presented to Congress separately from the 
     rest of the strategy.

     SEC. 1110. REQUIREMENT FOR SOUTHWEST BORDER COUNTERNARCOTICS 
                   STRATEGY.

       (a) In General.--Not later than 120 days after the date of 
     enactment of this Act, and every 2 years thereafter, the 
     Director of National Drug Control Policy shall submit to the 
     Congress a Southwest Border Counternarcotics Strategy.
       (b) Purposes.--The Southwest Border Counternarcotics 
     Strategy shall--
       (1) set forth the Government's strategy for preventing the 
     illegal trafficking of drugs across the international border 
     between the United States and Mexico, including through ports 
     of entry and between ports of entry on that border;
       (2) state the specific roles and responsibilities of the 
     relevant National Drug Control Program agencies (as defined 
     in section 702 of the Office of National Drug Control Policy 
     Reauthorization Act of 1998 (21 U.S.C. 1701)) for 
     implementing that strategy; and
       (3) identify the specific resources required to enable the 
     relevant National Drug Control Program agencies to implement 
     that strategy.
       (c) Specific Content Related to Drug Tunnels Between the 
     United States and Mexico.--The Southwest Border 
     Counternarcotics Strategy shall include--
       (1) a strategy to end the construction and use of tunnels 
     and subterranean passages that cross the international border 
     between the United States and Mexico for the purpose of 
     illegal trafficking of drugs across such border; and
       (2) recommendations for criminal penalties for persons who 
     construct or use such a tunnel or subterranean passage for 
     such a purpose.
       (d) Consultation With Other Agencies.--The Director shall 
     issue the Southwest Border Counternarcotics Strategy in 
     consultation with the heads of the relevant National Drug 
     Control Program agencies.
       (e) Limitation.--The Southwest Border Counternarcotics 
     Strategy shall not change existing agency authorities or the 
     laws governing interagency relationships, but may include 
     recommendations about changes to such authorities or laws.
       (f) Report to Congress.--The Director shall provide a copy 
     of the Southwest Border Counternarcotics Strategy to the 
     appropriate congressional committees (as defined in section 
     702 of the Office of National Drug Control Policy 
     Reauthorization Act of 1998 (21 U.S.C. 1701)), and to the 
     Committee on Armed Services and the Committee on Homeland 
     Security of the House of Representatives, and the Committee 
     on Homeland Security and Governmental Affairs and the 
     Committee on Armed Services of the Senate.
       (g) Treatment of Classified or Law Enforcement Sensitive 
     Information.--Any content of the Southwest Border 
     Counternarcotics Strategy that involves information 
     classified under criteria established by an Executive order, 
     or whose public disclosure, as determined by the Director or 
     the head of any relevant National Drug Control Program 
     agency, would be detrimental to the law enforcement or 
     national security activities of any Federal, State, local, or 
     tribal agency, shall be presented to Congress separately from 
     the rest of the strategy.

     SEC. 1111. REQUIREMENT FOR SCIENTIFIC STUDY OF MYCOHERBICIDE 
                   IN ILLICIT DRUG CROP ERADICATION.

       (a) Requirement.--Not later than 90 days after the date of 
     enactment of this Act, the Director of the Office of National 
     Drug Control Policy shall submit to the Congress a report 
     that includes a plan to conduct, on an expedited basis, a 
     scientific study of the use of mycoherbicide as a means of 
     illicit drug crop elimination by an appropriate Government 
     scientific research entity, including a complete and thorough 
     scientific peer review. The study shall include an evaluation 
     of the likely human health and environmental impacts of 
     mycoherbicides derived from fungus naturally existing in the 
     soil.
       (b) Study.--The study required by this section shall be 
     conducted in United States territory and not in any foreign 
     country.

     SEC. 1112. REQUIREMENT FOR STUDY OF STATE PRECURSOR CHEMICAL 
                   CONTROL LAWS.

       (a) Study.--The Director of National Drug Control Policy, 
     in consultation with the National Alliance for Model State 
     Drug Laws, shall conduct a study of State laws with respect 
     to precursor chemical controls.
       (b) Report.--Not later than 6 months after the date of the 
     enactment of this Act, the Director of National Drug Control 
     Policy shall submit a report to Congress on the results of 
     the study under subsection (a), including--
       (1) a comparison of the State laws studied and the 
     effectiveness of each such law; and
       (2) a list of best practices observed with respect to such 
     laws.

[[Page 22890]]



     SEC. 1113. REQUIREMENT FOR STUDY OF DRUG ENDANGERED CHILDREN 
                   PROGRAMS.

       (a) Study.--The Director of National Drug Control Policy 
     shall conduct a study of methamphetamine-related activities 
     that are conducted by different Drug Endangered Children 
     programs administered by States.
       (b) Report.--Not later than 6 months after the date of the 
     enactment of this Act, the Director of National Drug Control 
     Policy shall submit to Congress a report on the results of 
     the study under subsection (a). Such report shall include--
       (1) an analysis of the best practices of the activities 
     studied; and
       (2) recommendations for establishing a national policy to 
     address drug endangered children, based on the Drug 
     Endangered Children programs administered by States.
       (c) Definitions.--In this section--
       (1) the term ``methamphetamine-related activity'' means any 
     activity related to the production, use, or effects of 
     methamphetamine; and
       (2) the term ``drug endangered children'' means children 
     whose physical, mental, or emotional health are at risk 
     because of the production, use, or effects of methamphetamine 
     by another person.

     SEC. 1114. STUDY ON DRUG COURT HEARINGS IN NONTRADITIONAL 
                   PLACES.

       (a) Finding.--Congress finds that encouraging drug courts 
     and schools to enter into partnerships that allow students to 
     see the repercussions of drug abuse by non-violent offenders 
     may serve as a strong deterrent and promote demand reduction.
       (b) Study.--The Director of the Office of National Drug 
     Control Policy shall conduct a study on drug court programs 
     that conduct hearings in nontraditional public places, such 
     as schools. At a minimum, the study shall evaluate similar 
     programs in operation, such as the program operated in the 
     Fourth Judicial District Drug Court, in Washington County, 
     Arkansas.
       (c) Requirement.--At the same time the President submits to 
     Congress the National Drug Control Strategy due February 1, 
     2007, pursuant to section 706 of the Office of National Drug 
     Control Policy Reauthorization Act of 1998, the President 
     shall submit to Congress a report on the study conducted 
     under subsection (b). The report shall include an evaluation 
     of the results of the study and such recommendations as the 
     President considers appropriate.
       (d) Demand Reduction.--In this section, the term ``demand 
     reduction'' has the meaning provided in section 702(1) of the 
     Office of National Drug Control Policy Reauthorization Act of 
     1998 (21 U.S.C. 1701(1)).

     SEC. 1115. REPORT ON TRIBAL GOVERNMENT PARTICIPATION IN HIDTA 
                   PROCESS.

       (a) Report Requirement.--The Director of the Office of 
     National Drug Control Policy shall prepare a report for 
     Congress on the representation of tribal governments in the 
     High Intensity Drug Trafficking Areas Program and in high 
     intensity drug trafficking areas designated under that 
     Program. The report shall include--
       (1) a list of the tribal governments represented in the 
     Program and a description of the participation by such 
     governments in the Program;
       (2) an explanation of the rationale for the level of 
     representation by such governments; and
       (3) recommendations by the Director for methods for 
     increasing the number of tribal governments represented in 
     the Program.
       (b) Deadline.--The report prepared under subsection (a) 
     shall be submitted not later than 1 year after the date of 
     the enactment of this Act.
       (c) Definition.--In this section, the term ``High Intensity 
     Drug Trafficking Areas Program'' means the program 
     established under section 707 of the Office of National Drug 
     Control Policy Reauthorization Act of 1998 (21 U.S.C. 1706)

     SEC. 1116. REPORT ON SCHOOL DRUG TESTING.

       (a) Report Requirement.--The Director of National Drug 
     Control Policy shall prepare a report on drug testing in 
     schools. The report shall include a list of secondary schools 
     that have initiated drug testing from among those schools 
     that have attended conferences on drug testing sponsored by 
     the Office of National Drug Control Policy.
       (b) Deadline.--Not later than 120 days after the date of 
     the enactment of this Act, the Director of National Drug 
     Control Policy shall submit to Congress the report required 
     under subsection (a).

     SEC. 1117. REPORT ON ONDCP PERFORMANCE BONUSES.

       (a) Report Requirement.--The Director of National Drug 
     Control Policy shall prepare a report on performance bonuses 
     at the Office of National Drug Control Policy. The report 
     shall include a list of employees who received performance 
     bonuses, and the amount of such bonuses, for the period 
     beginning on October 1, 2004, and ending on the date of 
     submission of the report.
       (b) Deadline.--Not later than 120 days after the date of 
     the enactment of this Act, the Director of National Drug 
     Control Policy shall submit to Congress the report required 
     under subsection (a).

     SEC. 1118. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP 
                   OF ALL FEDERAL ADVERTISING OR OTHER 
                   COMMUNICATION MATERIALS.

       Section 712 is amended to read as follows:

     ``SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP 
                   OF ALL FEDERAL ADVERTISING OR OTHER 
                   COMMUNICATION MATERIALS.

       ``(a) Requirement.--Each advertisement or other 
     communication paid for by the Office, either directly or 
     through a contract awarded by the Office, shall include a 
     prominent notice informing the target audience that the 
     advertisement or other communication is paid for by the 
     Office.
       ``(b) Advertisement or Other Communication.--In this 
     section, the term `advertisement or other communication' 
     includes--
       ``(1) an advertisement disseminated in any form, including 
     print or by any electronic means; and
       ``(2) a communication by an individual in any form, 
     including speech, print, or by any electronic means.''.

     SEC. 1119. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL 
                   PARTNERSHIPS TO COERCE ABSTINENCE IN CHRONIC 
                   HARD-DRUG USERS UNDER COMMUNITY SUPERVISION 
                   THROUGH THE USE OF DRUG TESTING AND SANCTIONS.

       At the end of the Act, insert the following:

     ``SEC. 716. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL 
                   PARTNERSHIPS TO COERCE ABSTINENCE IN CHRONIC 
                   HARD-DRUG USERS UNDER COMMUNITY SUPERVISION 
                   THROUGH THE USE OF DRUG TESTING AND SANCTIONS.

       ``(a) Awards Required.--The Director shall make competitive 
     awards to fund demonstration programs by eligible 
     partnerships for the purpose of reducing the use of illicit 
     drugs by chronic hard-drug users living in the community 
     while under the supervision of the criminal justice system.
       ``(b) Use of Award Amounts.--Award amounts received under 
     this section shall be used--
       ``(1) to support the efforts of the agencies, 
     organizations, and researchers included in the eligible 
     partnership;
       ``(2) to develop and field a drug testing and graduated 
     sanctions program for chronic hard-drug users living in the 
     community under criminal justice supervision; and
       ``(3) to assist individuals described in subsection (a) by 
     strengthening rehabilitation efforts through such means as 
     job training, drug treatment, or other services.
       ``(c) Eligible Partnership Defined.--In this section, the 
     term `eligible partnership' means a working group whose 
     application to the Director--
       ``(1) identifies the roles played, and certifies the 
     involvement of, two or more agencies or organizations, which 
     may include--
       ``(A) State, local, or tribal agencies (such as those 
     carrying out police, probation, prosecution, courts, 
     corrections, parole, or treatment functions);
       ``(B) Federal agencies (such as the Drug Enforcement 
     Agency, the Bureau of Alcohol, Tobacco, Firearms, and 
     Explosives, and United States Attorney offices); and
       ``(C) community-based organizations;
       ``(2) includes a qualified researcher;
       ``(3) includes a plan for using judicial or other criminal 
     justice authority to administer drug tests to individuals 
     described in subsection (a) at least twice a week, and to 
     swiftly and certainly impose a known set of graduated 
     sanctions for non-compliance with community-release 
     provisions relating to drug abstinence (whether imposed as a 
     pre-trial, probation, or parole condition or otherwise);
       ``(4) includes a strategy for responding to a range of 
     substance use and abuse problems and a range of criminal 
     histories;
       ``(5) includes a plan for integrating data infrastructure 
     among the agencies and organizations included in the eligible 
     partnership to enable seamless, real-time tracking of 
     individuals described in subsection (a);
       ``(6) includes a plan to monitor and measure the progress 
     toward reducing the percentage of the population of 
     individuals described in subsection (a) who, upon being 
     summoned for a drug test, either fail to show up or who test 
     positive for drugs.
       ``(d) Reports to Congress.--
       ``(1) Interim report.--Not later than June 1, 2009, the 
     Director shall submit to Congress a report that identifies 
     the best practices in reducing the use of illicit drugs by 
     chronic hard-drug users, including the best practices 
     identified through the activities funded under this section.
       ``(2) Final report.--Not later than June 1, 2010, the 
     Director shall submit to Congress a report on the 
     demonstration programs funded under this section, including 
     on the matters specified in paragraph (1).
       ``(e) Authorization of Appropriations.--There is authorized 
     to be appropriated to carry out this section $4,900,000 for 
     each of fiscal years 2007 through 2009.''.

     SEC. 1120. POLICY RELATING TO SYRINGE EXCHANGE PROGRAMS.

       Section 703(a) (21 U.S.C. 1702(a)) is amended by adding at 
     the end the following:
     ``When developing the national drug control policy, any 
     policy of the Director relating to syringe exchange programs 
     for intravenous drug users shall be based on the best 
     available medical and scientific evidence regarding their 
     effectiveness in promoting individual health and preventing 
     the spread of infectious disease, and their impact on drug

[[Page 22891]]

     addiction and use. In making any policy relating to syringe 
     exchange programs, the Director shall consult with the 
     National Institutes of Health and the National Academy of 
     Sciences.''.

  The SPEAKER pro tempore. Pursuant to the rule, the gentleman from 
Indiana (Mr. Souder) and the gentleman from Maryland (Mr. Cummings) 
each will control 20 minutes.
  The Chair recognizes the gentleman from Indiana.


                             General Leave

  Mr. SOUDER. Madam Speaker, I ask unanimous consent that all Members 
may have 5 legislative days within which to revise and extend their 
remarks and include extraneous material on the bill under 
consideration.
  The SPEAKER pro tempore. Is there objection to the request of the 
gentleman from Indiana?
  There was no objection.
  Mr. SOUDER. Madam Speaker, I yield myself such time as I may consume.
  Madam Speaker, I would first like to thank Government Reform Chairman 
Tom Davis and Ranking Member Henry Waxman for working with us in the 
Drug Policy Subcommittee and gaining their support and assistance in 
passing this bipartisan bill.
  It is tough to pass bipartisan bills, particularly major legislation 
like this, at this time of year and in general. This authorization 
program is multiyear, $530 million directly and hundreds of millions 
more in some programs that were added to the original ONDCP bill, and 
to do something like that unanimously and have it be worked through 
both bodies has been an incredible accomplishment and an adventure.
  I would also like to thank Judiciary Chairman Sensenbrenner, as well 
as the minority, for waiving the right to go to the Judiciary 
Committee. I know that is rare, but in our negotiations with the 
Senate, we had multiple changes over the last few days, and that was a 
very important waiver. His staff and the staff of Senator Specter in 
the Senate have been very important allies in moving this bill. Also 
Senators Grassley, Biden, Leahy and Levin have made multiple changes in 
this bill in the last few days, all of which I think have helped 
improve this bill. I very much appreciate the bipartisan spirit with 
which we are trying to pass anti-drug legislation.
  Of course my friend and colleague, Congressman Elijah Cummings, the 
ranking member, and I have had a great working relationship these past 
few years and have been able to tackle one of the toughest issues that 
is hitting both urban America, suburban America and rural America, 
together, and build a very close friendship during these years too and 
a passion. I know from his experience in Baltimore seeing it firsthand 
as a State legislator and as a resident in the communities so hard hit, 
he brought a passion to this issue that has been very important. It has 
been a real privilege working together during this period.
  I now would like to read my opening statement.
  Across America, individuals, families and communities continue to be 
devastated by the scourge of drug abuse, and it remains one of the most 
pressing and unforgiving problems our country faces. This bill is 
largely the same language that the House passed on March 9 on a vote of 
399-5, with some improvements that came from negotiations with the 
other body and the administration.
  It is a forceful and bipartisan recommitment to our broad national 
efforts to control drug abuse and to renew our support for strong 
leadership from the Office of National Drug Control Policy, often known 
as the Drug Czar. By renewing this authorization, we believe we will 
soon see an even better coordination of the President's strategy to 
demonstrably reduce drug abuse by America's young people and to control 
its sad consequences.
  This reauthorization will preserve and improve our anti-drug efforts 
in a number of ways. It will preserve the success of the High Intensity 
Drug Trafficking Areas, or HIDTA programs.
  As the ONDCP's principal law enforcement program, HIDTA brings 
Federal, State, and local law enforcement together in specific high 
trafficking areas for sharing of intelligence and joint enforcement 
actions. It is perhaps the best model of governments working together 
in such a coordinated way, in a model that in Homeland Security we are 
attempting to duplicate but thus far have not had the same success. 
This bill keeps HIDTA in ONDCP where it belongs, focusing on 
dismantling drug trafficking organizations.
  It also provides a process for redirecting scarce funds to those 
HIDTA regions where the need is greatest, as well as enacting much-
needed performance measurements. It will refocus the National Youth 
Anti-Drug Media Campaign, which all of us see in radio and television 
and it is our principal program to reach young people on prevention. 
This bill clarifies the purposes of this campaign, establishing that it 
is intended for mass media advertising to direct and steer young people 
away from drug abuse. This will turn the campaign away from projects 
not related to such mass media advertising.
  It will strengthen the Southwest Border Counternarcotics Strategy. 
Perhaps you have heard that we don't exactly control the southwest 
border at this time. Increasingly, the drug trade and all its attendant 
violence and corruption is concentrating on the southwest border.
  This bill requires the director of ONDCP to issue within 120 days of 
enactment a strategy identifying how the government will deal with this 
narcotics problem on the border, the roles of the various agencies in 
it, and the resources needed.
  Quite frankly, it is astounding that such a southwest border strategy 
does not currently exist. It will elevate the rank and status of the 
ONDCP director because the director is tasked with coordinating the 
drug control efforts of numerous agencies, including Cabinet-level 
Departments.
  This bill designates that he has the same rank and status as a 
Cabinet officer. This does not interfere with the President's authority 
to determine the makeup of his Cabinet, but it does assure that the 
director will be able to work Department heads as an equal, which is 
critical when you are working with State, Defense, Judiciary, Homeland 
Security and the many other agencies. This is essential if he is to 
have full cooperation and teamwork from these other executive offices.
  It will improve effectiveness and accountability in drug treatment. 
The bill will enhance drug treatment programs by requiring, for the 
first time, a uniform system of evaluating the success of drug 
treatment.
  Further, it will prevent the director from certifying any Federal 
budget request related to drug treatment that does not provide for 
adequate result and accountability measures.
  I want to address a few other things that were added over the last 
few days with the Senate. One is the Drug Free Communities Act. This 
was developed by former Congressman Portman and Congressman Levin here 
and has been backed widely in this body.
  It usually has a separate reauthorization. It has been put into this 
bill. It is already under ONDCP, but it usually moves in a separate 
bill. It has been combined with this bill so we are also reauthorizing 
the Drug Free Communities bill, which is absolutely one of the most 
effective grass-roots prevention programs.
  It, along with drug free schools and the national media campaign, are 
our only prevention efforts. It reauthorizes the National Guard 
counterdrug schools, which uses our National Guard in different States. 
In Indiana they are very active in going into schools and is a 
supplement to the Drug Free Schools program. And it authorizes the U.S. 
Anti-doping Agency, which has been very critical in the steroids fight 
and something we have been pushing for to get national measurements and 
a more aggressive attitude towards abuse of steroids among young 
people, and this authorizes that agency.
  I once again want to thank all of those involved in this, 
particularly Ranking Member Cummings, Chairman Tom Davis, and Ranking 
Member Waxman of the full committee.
  Madam Speaker, I reserve the balance of my time.

[[Page 22892]]


  Mr. CUMMINGS. Madam Speaker, I yield myself such time as I may 
consume.
  Madam Speaker, I rise in strong support of H.R. 6344, as amended by 
the amendment of the gentleman from Indiana (Mr. Souder). This bill to 
reauthorize the Office of National Drug Control Policy and related 
anti-drug programs is the product of a bipartisan and bicameral process 
that began more than 3 years ago in the Government Reform Subcommittee 
on Criminal Justice, Drug Policy and Human Resources, on which I serve 
as the ranking minority member. For nearly that period of time, the 
office has operated without legislative authorization.
  I want to again thank and congratulate Chairman Souder. He talked 
about my passion. I had an opportunity to see his when we visited his 
district. He has spent just a phenomenal amount of time on this 
legislation and spent a lot of time on this problem that we suffer from 
in this country, and I want to thank him for his leadership, and his 
very strong leadership at that.
  I also want to thank our full committee chairman, Tom Davis, and the 
Government Reform ranking member, Mr. Henry Waxman, for their strong 
leadership and cooperation in shaping a bill that we were able to 
report out of committee and pass on the House floor with strong 
bipartisan support.

                              {time}  1600

  This legislation incorporates additions and modifications negotiated 
with the Senate Republicans and Democrats, most notably Senators 
Grassley, Hatch, Biden, Leahy, and Levin.
  At its core, the bill before us today is substantially the same as 
the legislation passed by the House on March 9. The bill reauthorizes 
the drug czar's office for 5 years and also reauthorizes several key 
anti-drug programs managed by ONDCP, including the National Youth Anti-
Drug Media Campaign, the High Intensity Drug Trafficking Areas, or 
HIDTA program, and the Counterdrug Technology Assessment Center. In 
addition to authorizing funding for these programs, the bill contains 
provisions to strengthen them and make them more accountable.
  ONDCP, as the central coordinating body for drug control strategy in 
the White House, plays a vital role in shaping the Federal response to 
a national drug problem that claims more than 20,000 American lives 
each year. Through its formulation of the National Drug Control 
Strategy and its authority to certify the drug control budgets of 
agencies throughout the executive branch, ONDCP provides critical 
guidance and support to our efforts to address illegal drug abuse 
through programs in the areas of prevention, treatment, domestic law 
enforcement, interdiction, and international supply reduction efforts. 
We are taking an important step by reauthorizing the drug czar's office 
today.
  I am especially pleased that this bill preserves bipartisan 
agreements achieved through good faith negotiations during committee 
consideration of the bill, including a provision to ensure that funds 
for the National Youth Anti-Drug Media Campaign are not used to 
advocate for or against any candidate or legislative or regulatory 
measure.
  I am also pleased that we will finally pass the Dawson Family 
Community Protection Act which authorizes $7 million of HIDTA program 
funds to be devoted to supporting efforts to improve safety and 
facilitate cooperation with police and communities ravaged by drug 
violence.
  This provision memorializes the courageous efforts of Angela Dawson, 
a Baltimore City resident, who along with her husband and five children 
lost her life when a drug dealer fire-bombed the family's home in 
retaliation for Ms. Dawson's reporting of drug distribution activities 
in the immediate vicinity of her home. I might add that Ms. Dawson's 
home is within a mile of my home.
  HIDTA plays a vital role in combating drug trafficking in many areas 
of the country, and this provision will help to ensure that funds are 
available to address urgent threats to community safety due to drug 
violence.
  The amendments adopted by the other body augment and mainly improve 
upon the House-passed bill. This bill adds reauthorization of the Drug-
Free Communities Support Program, one of the most popular and effective 
Federal drug prevention programs that we have. One other addition 
included in this bill also deserves particular mention.
  The provision proposed by Senator Levin would amend the Controlled 
Substances Act to increase from 30 to 100 the number of patients to 
whom a doctor can prescribe buprenorphine, an extremely effective drug 
for the use of opiate addiction. This important and welcome change will 
have a tremendous impact in places like my own city of Baltimore where 
opiate addiction is far too common and access to treatment is far too 
limited. The bill would immediately triple the capacity of physicians 
to prescribe this drug for patients with opiate addiction and should 
have a substantial impact.
  The substitute amendment implements two further changes negotiated 
with the Senate in recent days. The first would modify a provision in 
the House-passed bill calling for a study of mycoherbicides, requiring 
that any testing be conducted inside the United States. The second 
would restore a provision offered by Mr. Waxman that would require 
ONDCP to consult with the National Institutes of Health and the 
National Academy of Sciences when formulating policy on syringe 
exchange programs aimed at preventing HIV transmission among injection 
drug users. The provision calls for ONDCP to base any decisions on the 
scientific evidence regarding the efficacy of syringe exchange and its 
impact on drug use.
  Madam Speaker, the devastating impact of drugs on communities 
throughout this Nation is difficult to overstate. In some communities, 
drugs are a quiet, invisible, disruptive force. In others, as in the 
case of America's inner cities and rural communities afflicted by meth, 
it is impossible not to see, and it is impossible not to feel the pain. 
But no community is completely untouched or immune from this problem.
  I am confident that this bill will preserve and strengthen our 
Nation's most essential tools for fighting the good fight against drug 
abuse and related crime and social problems.
  I am also very pleased about the provisions with regard to 
accountability for drug treatment. Mr. Souder and I have agreed over 
and over again and done everything in our power to make sure that if 
there is going to be drug treatment, that that drug treatment be 
effective and efficient. We wanted to make sure that those who go into 
treatment came out better off than what they went in.
  One of the things that I have discovered as an elected official and 
talking to many addicts is they go into drug treatment, and they feel 
they have not been treated properly or that the treatment has not been 
effective. That makes them reluctant to go into treatment again if need 
be, and at the same time, many of them would not have gotten better. 
That is not to take away from the many, many great organizations that 
are doing a great job of treating drug-addicted folks, but we just want 
to make sure that when America's taxpayers' dollars are spent, that 
they are spent, again, in an effective and efficient manner, but we 
also want something else. We want to make sure that those people who 
find themselves in the clutches of drug addiction are able to depend 
upon treatment that can best help them.
  So I applaud my colleagues on both sides of the aisle and in both 
Houses for their cooperative efforts, and I again want to thank Mr. 
Souder for all the hard work. We have come now to what appears to be an 
end to a long journey, but I am hopeful that what we have done in this 
bill will affect generations yet unborn, for there are so many people 
that will never know what we were able to accomplish in this 
legislation, but they will be affected and they will be able to raise 
their families, hopefully get back to work, do the things that 
productive citizens do, and perhaps, just perhaps, another generation

[[Page 22893]]

of folk who may have gone into drugs, we may have just prevented some 
of that.
  Madam Speaker, I reserve the balance of my time.
  Mr. SOUDER. Madam Speaker, I yield myself such time as I may consume.
  I wanted to make a couple of additional comments before I yield back 
fully. This is a very comprehensive bill. It includes many programs 
that Members are familiar with in their districts but they may not have 
realized was under the Office of National Drug Control Policy.
  One is the Counterdrug Technology Assessment Center. That is the 
primary resource of the United States Government that transfers 
technology to your local law enforcement. It has also been a great 
model. This bill requires it to be coordinated more closely with 
homeland security.
  Quite frankly, I think one of the challenges in the homeland security 
is to make sure that they do what we have done in narcotics 
enforcement. And that is, if a local small town wants certain equipment 
because they think it is a fancy gadget, there is a review process that 
says that is not really what you need; this is more likely to effect 
and impact the type of narcotics enforcement you need in your 
community. But it is the primary transfer program for technology and a 
great model, and it reauthorizes that.
  Also, we have had an exasperating 3-year fight with the drug czar 
over the lack of coordination in this administration on 
methamphetamine. There is a section here, approximately 4\1/2\ pages 
long, in the National Methamphetamine Information Clearinghouse Act. 
While the Combat Meth Act we passed in coordination with many State 
acts have at least leveled off and in some States resulted, actually 
resulted in a drop in the so-called mom-and-pop labs that are home 
grown, in some States they are still coming in. Florida has had an 
expansion. Some of this is to moving to Internet and some to crystal 
meth.
  We have had no clearinghouse in the United States Government that 
worked with meth. This bill will add, in addition the our Combat Meth 
Act, it will put the office of the national director, who is supposed 
to be in charge of narcotics, in a position of having an organized 
effort now on methamphetamine, which has been in every State an 
increasing major threat to so many families. It has sections on drug-
endangered children and others.
  Approximately 75 to 90 percent of all crime in America is related or 
at least enabled by drug and alcohol abuse; that in many States where 
we had hearings as many as 80 percent of the kids in child custody 
protection were because of meth or other drug abuse and danger to 
children. We heard horror stories about people high on narcotics who 
even put their baby children in a stove or others to warm them up 
because they were so wiped out. The Dawson family in Baltimore who were 
fire-bombed because they were afraid they were going to be witnesses in 
a case.
  This bill addresses most of those things. It is absolutely essential 
that we get this department reauthorized with some guidelines because, 
unless Congress does its work, there are no guidelines on the executive 
branch to try to respond to what we are hearing in our grass roots.
  So, once again, I want to thank Mr. Cummings, Mr. Davis, Mr. Waxman 
and those in the Senate who have worked so long and hard on this, and I 
urge all Members to pass it.
  Madam Speaker, I reserve my time.
  Mr. CUMMINGS. Madam Speaker, I yield 5 minutes to the distinguished 
gentleman from Illinois (Mr. Davis), a member of our subcommittee who 
has worked tirelessly on this issue and has just been a real champion.
  Mr. DAVIS of Illinois. Madam Speaker, first of all, I want to thank 
the gentleman from Maryland for yielding.
  I also want to commend Chairman Souder and Ranking Member Cummings 
for the tenacious and outstanding work that they have done on this 
issue ever since I have been associated with them and affiliated with 
the subcommittee. As a matter of fact, they have traveled all over 
America, the length and breadth of the country, listening to people, 
visiting with people. As a matter of fact, I do not know anybody who 
has worked harder on an issue than they have, and so I commend both of 
you for your tenacity and outstanding work.
  I rise in support of H.R. 2829, Drug Control Policy Reauthorization 
Act of 2005, a policy which addresses prevention, interdiction and 
treatment, as well as all aspects of law enforcement.
  The use and abuse of illegal, illicit and contraband drugs is one of 
the most challenging and difficult problems facing America. For 
example, in Cook County where I live, in a survey that was taken a 
couple of years ago, 800,000 individuals indicated that they used 
drugs, 800,000. I grant you that we have a population of over 5 million 
people but 800,000 of those said that they used illicit drugs; 300,000 
indicated that they were what we call hard core drug users, every day 
or whenever they could find the money to purchase what they need. As a 
matter of fact, the Chicago police records suggest that 75 percent of 
all the people that they arrest test positive for drug use.
  If we could somehow or another reduce the use of drugs, crime 
statistics would go so far down until sometimes we would have a hard 
time finding them. There is a direct correlation between crime and drug 
use in America.
  As a result of looking at this problem, I have become more and more a 
fan of what I call treatment on demand; that is, enough resources so 
that when individuals who are addicted decide that they are ready for 
treatment, that treatment is available to them and so that they do not 
have to wait 90 days or 60 days to get into a program, because in 90 
days or 60 days or 30 days they may have decided that they do not want 
treatment anymore. So we lose the opportunity.
  While again I commend Chairman Souder, Ranking Member Cummings and 
certainly Chairman Tom Davis and Ranking Member Henry Waxman for all of 
the attention that they have given, I hope that as we go into the new 
Congress in January that we can build upon the outstanding work that 
this subcommittee and the Committee on Government Reform has done and 
make certain that we have not only the resources available for law 
enforcement for prevention but that we also have enough resources 
available for treatment.

                              {time}  1615

  Mr. SOUDER. Madam Speaker, I reserve the balance of my time.
  Mr. CUMMINGS. Madam Speaker, may I inquire as to how much time we 
have.
  The SPEAKER pro tempore. The gentleman from Maryland has 6 minutes 
remaining.
  Mr. SOUDER. Has the gentleman closed on the other side?
  The SPEAKER pro tempore. And the gentleman from Indiana has 10 
minutes remaining.
  Mr. CUMMINGS. I just want to say this, Madam Speaker. One of the 
things that we were concerned about was our HIDTA programs, High 
Intensity Drug Trafficking Areas. When we saw the budget, the budget 
basically cut substantially the funds for HIDTA, and we in our 
subcommittee and in our committee have seen the great work of the HIDTA 
throughout our country and we were determined to make sure that they 
stayed intact and continued to do the jobs that they have done so 
effectively.
  One of the good things about HIDTA is that they are able to bring 
together our Federal, our local, and our State law enforcement officers 
so they can work together. And, again, going back to our taxpayers' tax 
dollars, to use those dollars effectively and efficiently to fight drug 
violence and drug crimes, crimes related to drugs.
  But as I sat and listened to Congressman Davis and certainly to Mr. 
Souder, I could not help but be reminded of just about 4 months ago as 
I was standing in my district in a supermarket and a young man standing 
in front of me was talking to me saying he was looking for a job, and 
he pulled up his shirt and he showed me the barrel of a gun. And as he 
was standing

[[Page 22894]]

there, he said, I am looking for a job because I simply do not want to 
continue to go around sticking up people to feed my drug habit.
  That thing really shook me up, because when you have got somebody 
possibly committing two or three robberies a day, as he told me, that 
says a lot. And I think that we fail sometimes to understand how deep 
this problem is and how it goes against the very safety of all of our 
residents, no matter where they may live. And if there is anything that 
I have learned from being on this subcommittee, it is that there are no 
boundaries. There really are no boundaries with regard to drug 
addiction and the problem of drugs. One of the things that I know Mr. 
Souder will agree with me, when we got so much interest from our 
friends in the Congress who are seeing just a terrible problem with 
methamphetamines, they have come forth and they have been very, very 
helpful in helping us to figure out how to address not only the 
problems of methamphetamines, but the problems associated with heroin, 
associated with crack cocaine, with cocaine, and so many other drugs.
  So I think that all of us have to understand that, no matter where we 
may live or who we may represent, that we all may have different 
problems but still we need to work together to address those problems 
in a way that is effective for all of us, because, again, we are trying 
to heal the Nation and heal those people who have again found 
themselves in the clutches of this horrible, horrible situation.
  Madam Speaker, I yield back the balance of my time.
  Mr. SOUDER. Madam Speaker, today before we passed H.R. 6344, I took 
the opportunity to thank the various members of the House and Senate, 
without whom we could not have passed this important and long-overdue 
legislation. As a point of personal privilege, I want to take this 
opportunity to thank the many staff members who worked so long and so 
hard for us.
  First, I must thank the Staff director of our Subcommittee on 
Criminal Justice, Drug Policy and Human Resources. Marc Wheat has been 
with us for over three years, and he has been relentless and energetic 
in pursuing this daunting project. There is no other staffer on the 
House or Senate side who deserves more credit.
  Subcommittee counsel Dennis Kilcoyne, who joined our staff in 
February, has led the negotiations with the Senate for months and 
skillfully steered this legislation through the demands and critiques 
of the many competing parties in Congress, the Administration and 
private sector. It was a huge task requiring patience, skill and 
diplomacy, without which the effort would not have succeeded.
  The bipartisan nature of this negotiation has been an inspiration, 
and that is represented on the House side by Tony Haywood, counsel to 
the minority staff of the Government Reform Committee, who has ably 
represented the interests of our ranking Subcommittee member, Elijah 
Cummings. He has been a team player with our staff.
  I cannot forget the role played by our former Staff Director Chris 
Donesa--now with the House Intelligence Committee--and our former 
Subcommittee counsel Nick Coleman. These men brought great insight and 
skill that has contributed much to this legislation.
  And I would be remiss if I didn't thank Susie Schulte of the 
Government Reform Committee and Matt Miller of the Speaker's Drug Task 
Force, as well as his predecessor Andy Tiongson. All of these people 
have been enthusiastic and resourceful partners in this fight.
  Finally, I must mention all those staff members on the Senate side 
who responded so well to the hard work of our House Staff. First, I 
must thank Gavin Young--who represents Chairman Specter on the 
Judiciary Committee--and his predecessor Matt McPhillips, who just left 
last week to take up his FBI assignment in Denver. These two proved 
every bit as skillful in shepherding the bill in the last few weeks of 
maneuvering in that mysterious body we call the United States Senate.
  Also we thank Jeremy Mischler and Melissa Sundberg of the Senate Drug 
Caucus. They have worked long on behalf of Senator Grassley to help us 
finally reach the elusive goal of passing this bill.
  Jackie Parker of Senator Levin's staff and Reagan Taylor of Senator 
Biden's staff have been working this issue for a long time, and my 
staff have nothing but high praise for their team efforts. Roscoe Jones 
of Senator Leahy's staff worked hard and in good faith in recent weeks 
with my staff to hammer out the last few wrinkles in the negotiations, 
and we thank him for his efforts also.
  I also want to salute John Mackey of the House International 
Relations Committee, Janice O'Connell of the Senate Foreign Relations 
Committee, and Tim Rieser of the Senate Appropriations Foreign 
Operations Subcommittee, who did so much in the drafting of the 
provisions to ensure that the Director of ONDCP carries out a study on 
the use of mycoherbicides as a way to kill off coca and opium poppy 
plants in an environmentally safe manner. Their efforts may succeed 
where thousands of tons of chemical spraying has failed.
  Among the private sector groups, we are especially grateful to Sue 
Thau of the Community Anti-Drug Coalitions of America, Marcia Lee 
Taylor of the Partnership for a Drug-Free America, and Ron Brooks of 
the National Narcotics Officers Associations Coalitions. From the 
treatment, prevention and law enforcement sides--respectively--they 
have been indispensable partners in our efforts to enact this law. 
Additionally, I must thank Professor Charles O'Keeffe of Virginia 
Commonwealth University, who gave us such helpful guidance on 
provisions to allow doctors to treat more heroin addicts who needs 
drugs like buprenorphine for treatment.
  Finally, I am particularly proud that this Act to be signed by the 
President takes the first step to prevent what C. S. Lewis referred to 
as ``the abolition of Man.'' In the section authorizing the U.S. Anti-
Doping Agency, it explicitly bans from athletic competition anyone who 
has been genetically modified for performance enhancement. This 
technology of ``gene-doping'' is not yet viable in humans, but it is 
widely anticipated to be on the horizon. To that end, it is critical to 
anticipate the problem and explicitly address it.
  The protocol set by the U.S. Anti Doping Agency, which follows the 
World Anti-Doping Agency, is also the standard followed by the 
International Olympic Committee. These standards state that ``The non-
therapeutic use of cells, genes, genetic elements, or of the modulation 
of gene expression, having the capacity to enhance athletic 
performance, is prohibited.'' Although the U.S. Anti Doping Agency and 
the World Anti-Doping Agency presently prohibit gene-doping, there is 
no guarantee that gene-doping will remain on the prohibited list. The 
prohibition of gene-doping by statute and further public dialogue is 
critical. I salute my House and Senate colleagues for their foresighted 
efforts in this regard.
  I urge all Members to support the passage of H.R. 6344, as amended, 
and I yield back the balance of my time.
  The SPEAKER pro tempore. The question is on the motion offered by the 
gentleman from Indiana (Mr. Souder) that the House suspend the rules 
and pass the bill, H.R. 6344, as amended.
  The question was taken; and (two-thirds of those voting having 
responded in the affirmative) the rules were suspended and the bill, as 
amended, was passed.
  A motion to reconsider was laid on the table.

                          ____________________